Botulinum Toxin For Treating Postherpetic Neuralgia

Abstract

Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.

Description

RELATED APPLICATION

[0001] The present application is continuation in part of application Ser. No. 09/730,237 filed Dec. 5, 2000, the disclosure of which is incorporated, in its entirety, herein by reference.

BACKGROUND OF THE INVENTION

[0002] Botulinum Toxin {tc "Botulinum Toxin" \l 5}

[0003] The anaerobic, Gram positive bacterium Clostridium botulinum toxin, which causes a neuroparalytic illness in humans and animals referred to as botulism. The spores of Clostridium botulinum are found in soil and can grow in improperly sterilized and sealed food containers of home based canneries, which are the cause of many of the cases of botulism. The effects of botulism typically appear 18 to 36 hours after eating the foodstuffs infected with a Clostridium botulinum culture or spores. The botulinum toxin can apparently pass unattenuated through the lining of the gut and attack peripheral motor neurons. Symptoms of botulinum toxin intoxication can progress from difficulty walking, swallowing, and speaking to paralysis of the respiratory muscles and death.

[0004] BoNT/A is the most lethal natural biological agent known to man. About 50 picograms of botulinum toxin (purified neurotoxin complex) serotype A is a LD.sub.50 in mice. One unit (U) of botulinum toxin is defined as the amount of toxin that kills 50% of mice upon intraperitoneal injection into female Swiss webster mice weighing 18-20 grams each. Seven immunologically distinct botulinum neurotoxins have been characterized, these being respectively botulinum neurotoxin serotypes, A, B, C, D, E, F and G each of which is distinguished by neutralization with serotype-specific antibodies. The different serotypes of botulinum toxin vary in the animal species that they affect and in the severity and duration of the paralysis they evoke. For example, it has been determined that BoNt/A is 500 times more potent, as measured by the rate of paralysis produced in the rat, than is botulinum toxin serotype B (BoNT/B).

[0005] Additionally, BoNt/B has been determined to be non-toxic in primates at a dose of 480 U/kg which is about 12 times the primate LD.sub.50 for BoNt/A. Botulinum toxin apparently binds with high affinity to cholinergic motor neurons, is translocated into the neuron and blocks the release of acetylcholine.

[0006] Botulinum toxins have been used in clinical settings for the treatment of neuromuscular disorders characterized by hyperactive skeletal muscles. BoNt/A has been approved by the U.S. Food and Drug Administration for the treatment of blepharospasm, strabismus and hemifacial spasm. Non-serotype A botulinum toxin serotypes apparently have a lower potency and/or a shorter duration of activity as compared to BoNt/A. Clinical effects of peripheral intramuscular BoNt/A are usually seen within one week of injection. The typical duration of symptomatic relief from a single intramuscular injection of BoNt/A averages about three months.

[0007] Although all the botulinum toxins serotypes apparently inhibit release of the neurotransmitter acetylcholine at the neuromuscular junction, they do so by affecting different neurosecretory proteins and/or cleaving these proteins at different sites. For example, botulinum serotypes A and E both cleave the 25 kiloDalton (kD) synaptosomal associated protein (SNAP-25), but they target different amino acid sequences within this protein. BoNT/B, D, F and G act on vesicle-associated protein (VAMP, also called synaptobrevin), with each serotype cleaving the protein at a different site. Finally, botulinum toxin serotype C.sub.1 (BoNT/C.sub.1) has been shown to cleave both syntaxin and SNAP-25. These differences in mechanism of action may affect the relative potency and/or duration of action of the various botulinum toxin serotypes.

[0008] Regardless of serotype, the molecular mechanism of toxin intoxication appears to be similar and to involve at least three steps or stages. In the first step of the process, the toxin binds to the pre-synaptic membrane of the target neuron through a specific interaction between the H chain and a cell surface receptor; the receptor is thought to be different for each serotype of botulinum toxin and for tetanus toxin. The carboxyl end segment of the H chain, H.sub.C, appears to be important for targeting of the toxin to the cell surface.

[0009] In the second step, the toxin crosses the plasma membrane of the poisoned cell. The toxin is first engulfed by the cell through receptor-mediated endocytosis, and an endosome containing the toxin is formed. The toxin then escapes the endosome into the cytoplasm of the cell. This last step is thought to be mediated by the amino end segment of the H chain, H.sub.N, which triggers a conformational change of the toxin in response to a pH of about 5.5 or lower. Endosomes are known to possess a proton pump which decreases intra endosomal pH. The conformational shift exposes hydrophobic residues in the toxin, which permits the toxin to embed itself in the endosomal membrane. The toxin then translocates through the endosomal membrane into the cytosol.

[0010] The last step of the mechanism of botulinum toxin activity appears to involve reduction of the disulfide bond joining the H and L chain. The entire toxic activity of botulinum and tetanus toxins is contained in the L chain of the holotoxin; the L chain is a zinc (Zn++) endopeptidase which selectively cleaves proteins essential for recognition and docking of neurotransmitter-containing vesicles with the cytoplasmic surface of the plasma membrane, and fusion of the vesicles with the plasma membrane. Tetanus neurotoxin, botulinum toxin/B/D,/F, and/G cause degradation of synaptobrevin (also called vesicle-associated membrane protein (VAMP)), a synaptosomal membrane protein. Most of the VAMP present at the cytosolic surface of the synaptic vesicle is removed as a result of any one of these cleavage events. Each toxin specifically cleaves a different bond.

[0011] The molecular weight of the botulinum toxin protein molecule, for all seven of the known botulinum toxin serotypes, is about 150 kD. Interestingly, the botulinum toxins are released by Clostridial bacterium as complexes comprising the 150 kD botulinum toxin protein molecule along with associated non-toxin proteins. Thus, the BoNt/A complex can be produced by Clostridial bacterium as 900 kD, 500 kD and 300 kD forms. BoNT/B and C, are apparently produced as only a 500 kD complex. BoNT/D is produced as both 300 kD and 500 kD complexes. Finally, BoNT/E and F are produced as only approximately 300 kD complexes. The complexes (i.e. molecular weight greater than about 150 kD) are believed to contain a non-toxin hemaglutinin protein and a non-toxin and non-toxic nonhemaglutinin protein. These two non-toxin proteins (which along with the botulinum toxin molecule comprise the relevant neurotoxin complex) may act to provide stability against denaturation to the botulinum toxin molecule and protection against digestive acids when toxin is ingested. Additionally, it is possible that the larger (greater than about 150 kD molecular weight) botulinum toxin complexes may result in a slower rate of diffusion of the botulinum toxin away from a site of intramuscular injection of a botulinum toxin complex.

[0012] In vitro studies have indicated that botulinum toxin inhibits potassium cation induced release of both acetylcholine and norepinephrine from primary cell cultures of brainstem tissue. Additionally, it has been reported that botulinum toxin inhibits the evoked release of both glycine and glutamate in primary cultures of spinal cord neurons and that in brain synaptosome preparations botulinum toxin inhibits the release of each of the neurotransmitters acetylcholine, dopamine, norepinephrine, CGRP and glutamate.

[0013] BoNt/A can be obtained by establishing and growing cultures of Clostridium botulinum in a fermenter and then harvesting and purifying the fermented mixture in accordance with known procedures. All the botulinum toxin serotypes are initially synthesized as inactive single chain proteins which must be cleaved or nicked by proteases to become neuroactive. The bacterial strains that make botulinum toxin serotypes A and G possess endogenous proteases and serotypes A and G can therefore be recovered from bacterial cultures in predominantly their active form. In contrast, botulinum toxin serotypes C.sub.1, D and E are synthesized by nonproteolytic strains and are therefore typically unactivated when recovered from culture. Serotypes B and F are produced by both proteolytic and nonproteolytic strains and therefore can be recovered in either the active or inactive form. However, even the proteolytic strains that produce, for example, the BoNt/B serotype only cleave a portion of the toxin produced. The exact proportion of nicked to unnicked molecules depends on the length of incubation and the temperature of the culture. Therefore, a certain percentage of any preparation of, for example, the BoNt/B toxin is likely to be inactive, possibly accounting for the known significantly lower potency of BoNt/B as compared to BoNt/A. The presence of inactive botulinum toxin molecules in a clinical preparation will contribute to the overall protein load of the preparation, which has been linked to increased antigenicity, without contributing to its clinical efficacy. Additionally, it is known that BoNt/B has, upon intramuscular injection, a shorter duration of activity and is also less potent than BoNt/A at the same dose level.

[0014] It has been reported that BoNt/A has been used in clinical settings as follows:

[0015] (1) about 75-125 units of BOTOX.RTM..sup.1 per intramuscular injection (multiple muscles) to treat cervical dystonia; .sup.1Available from Allergen, Inc., of Irvine, Cal. under the tradename BOTOX.RTM..

[0016] (2) 5-10 units of BOTOX.RTM. per intramuscular injection to treat glabellar lines (brow furrows) (5 units injected intramuscularly into the procerus muscle and 10 units injected intramuscularly into each corrugator supercilii muscle);

[0017] (3) about 30-80 units of BOTOX.RTM. to treat constipation by intrasphincter injection of the puborectalis muscle;

[0018] (4) about 1-5 units per muscle of intramuscularly injected BOTOX.RTM. to treat blepharospasm by injecting the lateral pre-tarsal orbicularis oculi muscle of the upper lid and the lateral pre-tarsal orbicularis oculi of the lower lid.

[0019] (5) to treat strabismus, extraocular muscles have been injected intramuscularly with between about 1-5 units of BOTOX.RTM., the amount injected varying based upon both the size of the muscle to be injected and the extent of muscle paralysis desired (i.e. amount of diopter correction desired).

[0020] (6) to treat upper limb spasticity following stroke by intramuscular injections of BOTOX.RTM. into five different upper limb flexor muscles, as follows: [0021] (a) flexor digitorum profundus: 7.5 U to 30 U Available from Allergan, Inc., of Irvine, Calif. under the tradename BOTOX.RTM.. [0022] (b) flexor digitorum sublimus: 7.5 U to 30 U [0023] (c) flexor carpi ulnaris: 10 U to 40 U [0024] (d) flexor carpi radialis: 15 U to 60 U [0025] (e) biceps brachii: 50 U to 200 U. Each of the five indicated muscles has been injected at the same treatment session, so that the subject receives from 90 U to 360 U of upper limb flexor muscle BOTOX.RTM. by intramuscular injection at each treatment session.

[0026] The success of BoNt/A to treat a variety of clinical conditions has led to interest in other botulinum toxin serotypes. A study of two commercially available BoNT/A preparations (BOTOX.RTM. and Dysport.RTM.) and preparations of BoNT/B and F (both obtained from Wako Chemicals, Japan) has been carried out to determine local muscle weakening efficacy, safety and antigenic potential. Botulinum toxin preparations were injected into the head of the right gastrocnemius muscle (0.5 to 200.0 units/kg) and muscle weakness was assessed using the mouse digit abduction scoring assay (DAS). ED.sub.50 values were calculated from dose response curves. Additional mice were given intramuscular injections to determine LD.sub.50 doses. The therapeutic index was calculated as LD.sub.50/ED.sub.50. Separate groups of mice received hind limb injections of BOTOX.RTM. (5.0 to 10.0 units/kg) or BoNt/B (50.0 to 400.0 units/kg), and were tested for muscle weakness and increased water consumption, the later being a putative model for dry mouth. Antigenic potential was assessed by monthly intramuscular injections in rabbits (1.5 or 6.5 ng/kg for BoNt/B or 0.15 ng/kg for BOTOX.RTM.). Peak muscle weakness and duration were dose related for all serotypes. DAS ED.sub.50 values (units/kg) were as follows: BOTOX.RTM.: 6.7, Dysport.RTM.: 24.7, BoNt/B: 27.0 to 244.0, BoNT/F: 4.3. BOTOX.RTM. had a longer duration of action than BoNt/B or BoNt/F. Therapeutic index values were as follows: BOTOX.RTM.: 10.5, Dysport.RTM.: 6.3, BoNt/B: 3.2. Water consumption was greater in mice injected with BoNt/B than with BOTOX.RTM., although BoNt/B was less effective at weakening muscles. After four months of injections 2 of 4 (where treated with 1.5 ng/kg) and 4 of 4 (where treated with 6.5 ng/kg) rabbits developed antibodies against BoNt/B. In a separate study, 0 of 9 BOTOX.RTM. treated rabbits demonstrated antibodies against BoNt/A. DAS results indicate relative peak potencies of BoNt/A being equal to BoNt/F, and BoNt/F being greater than BoNt/B. With regard to duration of effect, BoNt/A was greater than BoNt/B, and BoNt/B duration of effect was greater than BoNt/F. As shown by the therapeutic index values, the two commercial preparations of BoNt/A (BOTOX.RTM. and Dysport.RTM.) are different. The increased water consumption behavior observed following hind limb injection of BoNt/B indicates that clinically significant amounts of this serotype entered the murine systemic circulation. The results also indicate that in order to achieve efficacy comparable to BoNt/A, it is necessary to increase doses of the other serotypes examined. Increased dosage can comprise safety. Furthermore, in rabbits, serotype B was more antigenic than was BOTOX.RTM., possibly because of the higher protein load injected to achieve an effective dose of BoNt/B.

[0027] The tetanus neurotoxin acts mainly in the central nervous system, while botulinum neurotoxin acts at the neuromuscular junction; both act by inhibiting acetylcholine release from the axon of the affected neuron into the synapse, resulting in paralysis. The effect of intoxication on the affected neuron is long-lasting and until recently has been thought to be irreversible. The tetanus neurotoxin is known to exist in one immunologically distinct serotype.

[0028] Acetylcholine

[0029] Typically only a single type of small molecule neurotransmitter is released by each type of neuron in the mammalian nervous system. The neurotransmitter acetylcholine is secreted by neurons in many areas of the brain, but specifically by the large pyramidal cells of the motor cortex, by several different neurons in the basal ganglia, by the motor neurons that innervate the skeletal muscles, by the preganglionic neurons of the autonomic nervous system (both sympathetic and parasympathetic), by the postganglionic neurons of the parasympathetic nervous system, and by some of the postganglionic neurons of the sympathetic nervous system. Essentially, only the postganglionic sympathetic nerve fibers to the sweat glands, the piloerector muscles and a few blood vessels are cholinergic and most of the postganglionic neurons of the sympathetic nervous system secret the neurotransmitter norepinephine. In most instances acetylcholine has an excitatory effect. However, acetylcholine is known to have inhibitory effects at some of the peripheral parasympathetic nerve endings, such as inhibition of the heart by the vagal nerve.

[0030] The efferent signals of the autonomic nervous system are transmitted to the body through either the sympathetic nervous system or the parasympathetic nervous system. The preganglionic neurons of the sympathetic nervous system extend from preganglionic sympathetic neuron cell bodies located in the intermediolateral horn of the spinal cord. The preganglionic sympathetic nerve fibers, extending from the cell body, synapse with postganglionic neurons located in either a paravertebral sympathetic ganglion or in a prevertebral ganglion. Since, the preganglionic neurons of both the sympathetic and parasympathetic nervous system are cholinergic, application of acetylcholine to the ganglia will excite both sympathetic and parasympathetic postganglionic neurons.

[0031] Acetylcholine activates two types of receptors, muscarinic and nicotinic receptors. The muscarinic receptors are found in all effector cells stimulated by the postganglionic neurons of the parasympathetic nervous system, as well as in those stimulated by the postganglionic cholinergic neurons of the sympathetic nervous system. The nicotinic receptors are found in the synapses between the preganglionic and postganglionic neurons of both the sympathetic and parasympathetic. The nicotinic receptors are also present in many membranes of skeletal muscle fibers at the neuromuscular junction.

[0032] Acetylcholine is released from cholinergic neurons when small, clear, intracellular vesicles fuse with the pre-synaptic neuronal cell membrane. A wide variety of non-neuronal secretory cells, such as, adrenal medulla (as well as the PC12 cell line) and pancreatic islet cells release catecholamines and insulin, respectively, from large dense-core vesicles. The PC12 cell line is a clone of rat pheochromocytoma cells extensively used as a tissue culture model for studies of sympathoadrenal development. Botulinum toxin inhibits the release of both types of compounds from both types of cells in vitro, permeabilized (as by electroporation) or by direct injection of the toxin into the denervated cell. Botulinum toxin is also known to block release of the neurotransmitter glutamate from cortical synaptosomes cell cultures.

[0033] A neuromuscular junction is formed in skeletal muscle by the proximity of axons to muscle cells. A signal transmitted through the nervous system results in an action potential at the terminal axon, with activation of ion channels and resulting release of the neurotransmitter acetylcholine from intraneuronal synaptic vesicles, for example at the motor endplate of the neuromuscular junction. The acetylcholine crosses the extracellular space to bind with acetylcholine receptor proteins on the surface of the muscle end plate. Once sufficient binding has occurred, an action potential of the muscle cell causes specific membrane ion channel changes, resulting in muscle cell contraction. The acetylcholine is then released from the muscle cells and metabolized by cholinesterases in the extracellular space. The metabolites are recycled back into the terminal axon for reprocessing into further acetylcholine.

[0034] Botulinum toxin has been shown to be effective in treating a number of conditions. For example, botulinum toxin may alleviate hyperhidrosis for up to 11 months. Odderson, Dermatol Surg (1988) 24:1237-1241, discloses that intracutaneous injections of botulinum toxin type A to the sweating area of the skin reduces excessive sweating; and Bushara et al., Clinical and Experimental Dermatology (1996) 21:276-278, disclose that subcutaneous injections of botulinum toxin type A can selectively denervate the local sweat glands to produce an anhidrotic patch.

[0035] Skin gene therapy is an effective method to directly deliver and transiently express genes in the skin. Several different delivery methods have been successfully used in recent years. Three of these delivery methods are needleless injection, topical gene delivery and direct gene delivery by injection using a needle.

[0036] In needleless injection delivery methods, microprojectile carrier particles may be coated with DNA encoding the desired gene and then discharged into the skin from an external delivery device. Depending on the discharge velocity and the distance from the injection site, the drug particles penetrate through the stratum corneum to different layers of the epidermis, dermis and underlying muscle. As the DNA-coated microprojectiles penetrate through epidermal and dermal cells, or are deposited in these cells, DNA is released and the encoded genes can be expressed. The cells potentially targeted by these drug particles in the epidermis include, but are not limited to keratinocytes, melanocytes and Langerhans cells. In the dermis fibroblasts, endothelial cells, adipocytes and dermal dendritic cells may be potential targets. If the microprojectiles penetrate through the dermis, underlying muscle cells could be targeted. One important aspect of this mechanism of delivery is that the DNA is directly delivered into the cell by penetration. Therefore, the issue of skin cell's ability to uptake DNA is not relevant. This means that all skin cells exposed to the DNA coated microprojectiles are potential targets.

[0037] In topical gene delivery, DNA can be applied to the skin as either a liposomal-DNA mixture or as an uncoated DNA for epicutaneous transfer into the epidermis. Primarily epidermal cells would be targeted with this delivery method. However, other cells may be targeted with needles

[0038] Gene delivery by injection with a needle is another method of gene delivery to the skin. With this method, the DNA is typically introduced directly into the dermis. Both epidermal and dermal cells have access to and can express the DNA. Electroinjection and electroporation methods of delivery are modifications of the direct injection method where a needle is used. These two methods can result in a higher level of gene expression than conventional injection using a needle. After intradermal injection of the DNA, electric pulses are applied to the injected area by electrodes for improved cellular uptake.

[0039] All these methods of gene delivery can be used for expression of botulinum toxin encoding DNA.

SUMMARY OF THE INVENTION

[0040] The present invention provides new and improved methods for the injection of botulinum toxin into an animal or human subject. The present invention also provides for methods for injecting botulinum toxin encoding DNA into an animal or human subject.

[0041] In accordance with the present invention, there are provided methods for treating a condition in an animal or human subject. These conditions may comprise pain, skeletal muscle conditions, smooth muscle conditions and glandular conditions. Botulinum toxins are also used for cosmetic purposes. The methods may comprise a step of administering a Clostridium neurotoxin component to the subject using a needleless syringe.

[0042] In one embodiment, the neurotoxin component is administered with a carrier, wherein the neurotoxin is coated on the carrier. In another embodiment, the neurotoxin is mixed with the carrier. The carrier may comprise a dense material, for example, gold, platinum, tungston or ice.

[0043] Still further in accordance with the present invention, the condition treated may be spasmodic dysphonia, laryngeal dystonia, oromandibular dysphonia, lingual dystonia, cervical dystonia, focal hand dystonia, blepharospasm, strabismus, hemifacial spasm, eyelid disorder, cerebral palsy, focal spasticity, spasmodic colitis, neurogenic bladder, anismus, limb spasticity, tics, tremors, bruxism, anal fissure, achalasia, fibromyalgia, dysphagia, lacrimation, hyperhydrosis, excessive salivation, excessive gastrointestinal secretions, excessive mucous secretion, pain from muscle spasms, headache pain, brow furrows and skin wrinkles.

[0044] Still further in accordance with the present invention, the neurotoxin component may be administered to the skin. The skin may comprise an epidermis layer, a dermis layer and a hypodermis layer.

[0045] In one embodiment, the neurotoxin component is administered to one or more layers of a skin where a nerve is located.

[0046] In another embodiment, the neurotoxin component is administered to a skin and substantially to a muscle tissue.

[0047] In still another embodiment, the neurotoxin component is administered to a muscle tissue.

[0048] Still further in accordance with the present invention, the neurotoxin component may be a difficile toxin, a butyricum toxin a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, or G or a variant thereof.

[0049] Still further in accordance with the present invention, the neurotoxin component may comprise a targeting component, a therapeutic component and a translocation component.

[0050] In one embodiment, the targeting component binds to a cell, for example, a nerve cell. In one embodiment the targeting component binds to a pre-synaptic nerve terminal. The pre-synaptic nerve terminal may belong to a cholinergic neuron.

[0051] The targeting component may comprise, for example, a carboxyl end segment of a heavy chain of a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0052] In one embodiment, the therapeutic component substantially interferes with exocytosis from a cell, for example, interfering with the release of neurotransmitters from a neuron or its terminals.

[0053] The therapeutic component may comprise, for example, a light chain of a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0054] In one embodiment, the translocation component facilitates transfer of at least a part of the neurotoxin component into the cytoplasm of a target cell.

[0055] The translocation component may comprise, for example, an amino end fragment of a heavy chain of a butyricum toxin, a tetanti toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0056] The targeting component may comprise, for example, a carboxyl end fragment of a heavy chain of a botulinum toxin type A, the therapeutic component may comprise a light chain of a botulinum toxin type A and the translocation component may comprise an amine end fragment of a heavy chain of botulinum toxin type A.

[0057] Still further in accordance with the present invention, the neurotoxin component may be recombinantly produced.

[0058] Still further in accordance with the present invention, are methods for expressing a recombinant DNA sequence encoding a Clostridium neurotoxin component in a cell of an animal in situ. The cell may be, for example, a skin cell, a muscle cell or a nerve cell.

[0059] In one embodiment, the DNA is administered to the animal by injection. For example, the injection may be by needleless injection.

[0060] Still further in accordance with the present invention, the DNA encoding neurotoxin component may be a difficile toxin, a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, or G or a variant thereof.

[0061] In one embodiment, the DNA encoding neurotoxin component comprises a targeting component, a therapeutic component and a translocation component.

[0062] Still further in accordance with the present invention, the targeting component may bind to a cell, for example, a nerve cell. In one embodiment, the targeting component binds to a pre-synaptic nerve terminal. The pre-synaptic nerve terminal may belong to a cholinergic neuron.

[0063] Still further in accordance with the present invention, the targeting component may comprise a carboxyl end segment of a heavy chain of a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0064] Still further in accordance with the present invention, the therapeutic component may substantially interfere with exocytosis from a cell, for example, interfering with the release of neurotransmitters from a neuron or its terminals.

[0065] The therapeutic component may comprise, for example, a light chain of a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0066] Still further in accordance with the present invention, the translocation component may facilitate transfer of at least a part of the neurotoxin component into the cytoplasm of a target cell.

[0067] The translocation component may comprise, for example, an amino end fragment of a heavy chain of a butyricum toxin, a tetnus toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0068] In one embodiment, the targeting component comprises a carboxyl end fragment of a heavy chain of a botulinum toxin type A, the therapeutic component comprises a light chain of a botulinum toxin type A, and the translocation component comprises an amine end fragment of a heavy chain of botulinum toxin type A.

[0069] Still further in accordance with the present invention, the neurotoxin component may be recombinantly produced.

[0070] Still further in accordance with the present invention, are compositions that may comprise a carrier and a Clostridial neurotoxin component, the composition may be useful for delivery of said neurotoxin component to a cell of an animal in situ.

[0071] The carrier may be a dense material for example gold, tungsten, platinum or ice crystal.

[0072] Still further in accordance with the present invention, the neurotoxin component may be a difficile toxin, a butyricum toxin a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, or G or a variant thereof.

[0073] Still further in accordance with the present invention, the neurotoxin component comprises a targeting component, a therapeutic component and a translocation component.

[0074] Still further in accordance with the present invention, the targeting component may bind to a cell, for example, a nerve cell. In one embodiment, the targeting component binds to pre-synaptic nerve terminal. The pre-synaptic nerve terminal may belong to a cholinergic neuron.

[0075] Still further in accordance with the present invention, the targeting component may comprise a carboxyl end segment of a heavy chain of a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0076] In one embodiment, the therapeutic component substantially interferes with exocytosis from a cell, for example, interfering with the release of neurotransmitters from a neuron or its terminals.

[0077] The therapeutic component may comprise, for example, a light chain of a butyricum toxin, a tetani toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0078] Still further in accordance with the present invention, the translocation component may facilitate transfer of at least a part of the neurotoxin component into the cytoplasm of a target cell.

[0079] The translocation component may comprise, for example, an amino end fragment of a heavy chain of a butyricum toxin, a tetanti toxin or a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof.

[0080] In one embodiment, the targeting component comprises a carboxyl end fragment of a heavy chain of a botulinum toxin type A, the therapeutic component comprises a light chain of a botulinum toxin type A, and the translocation component comprises an amine end fragment of a heavy chain of botulinum toxin type A.

[0081] Still further in accordance with the present invention, is a method to treat a condition in a subject comprising administering a therapeutically effective amount of DNA encoding a Clostridial neurotoxin component to a cell of an animal, for example, a human subject in situ. The cell may be, for example, a skin cell, a muscle cell or a nerve cell.

[0082] In one embodiment, the DNA is administered to the subject by injection. For example, the injection may be by needleless injection.

[0083] Still further in accordance with the present invention, the condition may comprise pain, skeletal muscle conditions, smooth muscle conditions and/or glandular conditions. In addition, DNA encoding a Clostridial neurotoxin may be administered to a subject for cosmetic purposes. For example, the condition may be spasmodic dysphonia, laryngeal dystonia, oromandibular dysphonia, lingual dystonia, cervical dystonia, focal hand dystonia, blepharospasm, strabismus, hemifacial spasm, eyelid disorder, cerebral palsy, focal spasticity, spasmodic colitis, neurogenic bladder, anismus, limb spasticity, tics, tremors, bruxism, anal fissure, achalasia, fibromyalgia, dysphagia, lacrimation, hyperhydrosis, excessive salivation, excessive gastrointestinal secretions, excessive mucous secretion, pain from muscle spasms, headache pain, brow furrows and skin wrinkles.

[0084] Still further in accordance with the present invention, are methods for immunization which include administering an effective amount of DNA encoding a Clostridial neurotoxin component to a tissue, for example, the skin, of a subject. The administering may be by injection, for example, by needleless injection.

[0085] Still further in accordance with the present invention, are compositions comprising a carrier and a DNA sequence encoding a Clostridial neurotoxin which may be useful for delivery of the DNA to a cell of a an animal or human subject in situ.

[0086] Still further in accordance with the present invention, the DNA encoding a neurotoxin may encode, for example, botulinum type A, B, C.sub.1, D, E, F, G or mixtures thereof or combinations thereof.

[0087] Any and all features described herein and combinations of such features are included within the scope of the invention provided that such features of any such combination are not mutually exclusive.

[0088] These and other aspects and advantages of the present invention are apparent in the following detailed description and claims.

DEFINITIONS

[0089] Before proceeding to describe the present invention, the following definitions are provided and apply herein.

[0090] "Affected skin area" means an area which may be in the vicinity of the area to be treated by needleless injection, for example, an area of skin at or near an area of skin with excessive sweating.

[0091] "Drug particle" means a drug, for example, a neurotoxin or, for example, a DNA sequence encoding a neurotoxin, alone, or in combination with one or more other substances, for example, gold.

[0092] "Without using a needle" or "needleless injection" means injecting a measurable amount of substance, for example, a carrier coated with a botulinum toxin without the use of a standard needle.

[0093] "Heavy chain" means the heavy chain of a Clostridial neurotoxin. It preferably has a molecular weight of about 100 kDa and may be referred to herein as H chain or as H.

[0094] "H.sub.N" means a fragment (preferably having a molecular weight of about 50 kDa) derived from the H chain of a Clostridial neurotoxin which is approximately equivalent to the amino terminal segment of the H chain, or the portion corresponding to that fragment in the intact in the H chain. It is believed to contain the portion of the natural or wild type Clostridial neurotoxin involved in the translocation of the L chain across an intracellular endosomal membrane.

[0095] "H.sub.C" means a fragment (about 50 kDa) derived from the H chain of a Clostridial neurotoxin which is approximately equivalent to the carboxyl terminal segment of the H chain, or the portion corresponding to that fragment in the intact H chain. It is believed to be immunogenic and to contain the portion of the natural or wild type Clostridial neurotoxin involved in high affinity, pre-synaptic binding to motor neurons.

[0096] "Light chain" means the light chain of a Clostridial neurotoxin. It preferably has a molecular weight of about 50 kDa, and can be referred to as L chain, L or as the proteolytic domain (amino acid sequence) of a Clostridial neurotoxin. The light chain is believed to be effective as an inhibitor of neurotransmitter release when it is released into a cytoplasm of a target cell.

[0097] "Neurotoxin" means a chemical entity that is capable of interfering with the functions of a neuron. For example, a neurotoxin may interfere with the transmission of an electrical signal from a nerve cell to its target.

[0098] The target may be, for example, another nerve cell, a tissue or an organ. The "neurotoxin" may be naturally occurring or other.

[0099] "Variant" means a chemical entity which is slightly different from a parent chemical entity but which still has a biological effect similar, or substantially similar to the biological effect of the chemical entity. The biological effect of the variant may be substantially the same or better than that of the parent. For example, a variant neurotoxin component may have one or more amino acid substitutions, amino acid modifications, amino acid deletions and/or amino acid additions. An amino acid substitution may be conservative or non-conservative, as is well understood in the art. In addition, variants of neurotoxin components may include neurotoxin components that have modified amino acid side chains, as is well known in the art. Variants may also include fragments.

[0100] An example of a variant neurotoxin component may comprise a variant light chain of a botulinum toxin having one or more amino acids substituted, modified, deleted and/or added. This variant light chain may have the same or better ability to prevent exocytosis, for example, the release of neurotransmitter vesicles. Additionally, the biological effect of a variant may be decreased compared to the parent chemical entity. For example, a variant light chain of a botulinum toxin type A having an amino acid sequence removed may have a shorter biological persistence than that of the parent (or native) botulinum toxin type A light chain.

[0101] "Fragment" means an amino acid or nucleotide sequence that comprises 1% or more of the parent amino acid or nucleotide sequence. For example, a fragment of botulinum toxin type A comprises 1% or more of the amino acid sequence of botulinum type A.

DETAILED DESCRIPTION OF THE INVENTION

[0102] Methods for administering neurotoxins, and DNA encoding neurotoxins, to animals, for example, humans are disclosed herein. In one broad embodiment, methods for administering neurotoxins include a step of administering a neurotoxin without using a needle. In another broad embodiment, there are provided methods of administering a DNA nucleotide sequence which encodes a neurotoxin to an animal or human subject.

[0103] Using these methods of administration, botulinum toxin can be used to treat a variety of conditions that are benefited by botulinum toxin treatment. For example, spasmodic dysphonia, laryngeal dystonia, oromandibular dysphonia, lingual dystonia, cervical dystonia, focal hand dystonia, blepharospasm, strabismus, hemifacial spasm, eyelid disorder, cerebral palsy, focal spasticity, spasmodic colitis, neurogenic bladder, anismus, limb spasticity, tics, tremors, bruxism, anal fissure, achalasia, fibromyalgia, dysphagia, lacrimation, hyperhydrosis, excessive salivation, excessive gastrointestinal secretions, as well as other secretory disorders, pain from muscle spasms, headache pain, brow furrows and skin wrinkles and other muscle tone disorders, and other disorders, characterized by involuntary movements of muscle groups may be treated using the present methods of administration. Further, the methods of administration of the present invention are useful for immunization against a neurotoxin.

[0104] The skin has two distinct layers and varies in thickness from about 1.5 to about 4 mm or more, depending on the regions of the body. The first layer is the superficial layer called the epidermis. It is a relatively thick epithelium. Deep to the epidermis is the second layer called the dermis. The dermis is a fibrous connective tissue and comprises sweat glands and nerves, or nerve terminals, innervating such sweat glands.

[0105] Just below the skin lies a fatty layer called the hypodermis, which may also be considered a part of a subcutaneous layer. Beneath the hypodermis or subcutaneous layer lies the deep fascial investment of the specialized structures of the body, for example the muscles.

[0106] Accordingly, the method of this invention delivers a neurotoxin, or DNA encoding a neurotoxin, to a tissue of an animal or a human subject. In one embodiment, the drug is delivered to the layer of the skin in which nerve terminals are found. For example, delivery is to the dermis layer. In another embodiment, delivery is to at least one layer of the skin and substantially to tissues beneath. For example, the administration to the dermis layer of the skin and to the subcutaneous layer. In another embodiment, delivery is to the skin and to muscle tissues beneath. In still another embodiment, delivery is substantially to the muscle tissue.

[0107] The administration of a composition comprising a carrier and a neurotoxin component and/or DNA encoding a neurotoxin component according to the invention may be accomplished through the use of a needleless injector.

[0108] Needleless injectors and their use are well known in the art. For example, Bellhouse et al. in U.S. Pat. Nos. 6,053,889 ('889), 6,013,050 ('050), 6,010,478 ('478), 6,004,286 ('286) and 5,899,880 ('880) disclose novel needleless injectors. The disclosures therein are incorporated in their entirety by reference herein. In one embodiment, the needleless injector comprises an elongated tubular nozzle and is connected to or capable of connection to a suitable energizing means for producing a supersonic gas flow, for example a burst of helium, which accelerates mediums to high velocity toward a skin surface and into the skin surface. Such a device may be purchased from PowderJect Pharmaceuticals, Oxford, UK. In one embodiment, the gas pressure provided must be sufficient to discharge the compositions into a targeted site, for example the dermis, but not so great as to damage the target. In another embodiment, the gas pressure provided is sufficient to deliver the compositions to a target site, for example the dermis, but not so great as to damage the skin surface, for example the epithelium. In another embodiment, the gas pressure is sufficient to deliver the compositions to the dermis layer, but not to the layers below, for example the subcutaneous layer and/or the muscle tissues. In another embodiment, the gas pressure provided must be sufficient to discharge the drug particles into a targeted site, for example the dermis and/or substantially to the muscle tissue below, but not so great as to damage the skin surface.

[0109] Advantages for using a needleless injector according to the present invention include, for example, an optimal delivery to a specific tissue layer, for example the dermis layer. Furthermore, in the case where the delivery is to the dermis and not the muscle tissues, the treatment may not cause a loss of motor function in the area being treated. Also, the use of a needleless injector according to the present invention improves clinical safety by eliminating the risk of infection from accidental injury with needles or from potential splash back of bodily fluids from liquid jet injectors, thereby avoiding the possibilities of cross-contamination of blood-borne pathogens such as HIV and hepatitis B. The needleless injector, such as the PowderJect System, also offers an optimal and specific delivery of drug particles to treat conditions with little pain or skin damage such as bruising or bleeding.

[0110] A drug particle may comprise a neurotoxin component and a carrier component. The neurotoxin may include a targeting component, a therapeutic component and a translocation component. The targeting component may bind to a pre-synaptic nerve terminal, for example a pre-synaptic nerve terminal of a cholinergic neuron. For example, the targeting component may include a carboxyl end segment of a heavy chain of a butyricum toxin, a tetani toxin, a botulinum toxin type A, B, C.sub.1, D, E, F, G, or a variant thereof. In a preferred embodiment, the targeting component comprises a carboxyl end segment of a heavy chain of a botulinum toxin type A.

[0111] The therapeutic component may substantially interfere with exocytosis from a cell, for example, interfering with the release of neurotransmitters from a neuron or its terminals. For example, the therapeutic component may include a light chain of a butyricum toxin, a tetani toxin, a botulinum toxin type A, B, C.sub.1, D, E, F, G, or a variant thereof. In a preferred embodiment, the therapeutic component comprises a light chain of a botulinum toxin type A.

[0112] The translocation component may facilitate the transfer of at least a part of the neurotoxin into the cytoplasm of the target cell. For example, the translocation component may include an amino end fragment of a heavy chain of a butyricum toxin, a tetani toxin, a botulinum toxin type A, B, C.sub.1, D, E, F, G or a variant thereof. In a preferred embodiment, the translocation component comprises an amino end fragment of a heavy chain of a botulinum toxin type A.

[0113] In one embodiment, the targeting component comprises a carboxyl end fragment of a heavy chain of a botulinum toxin type A, the therapeutic component comprises a light chain of a botulinum toxin type A and the translocation component comprises an amine end fragment of a heavy chain of a botulinum toxin type A. In a preferred embodiment, the neurotoxin of the present invention comprises a botulinum toxin type A. For example, very useful botulinum toxin type A may be obtained from Allergan, Inc., under the trade name BOTOX.RTM..

[0114] In another broad aspect of this invention, recombinant techniques are used to produce at least one of the components of the neurotoxins. The technique includes steps of obtaining DNA sequences which encode at least one of the neurotoxin components, for example the therapeutic component, translocation component and/or targeting component. The DNA encoding the neurotoxin is inserted into an expression vector with compatible cohesive end terminals that will allow for the annealing and subsequent ligation of the neurotoxin encoding DNA insert. After ligation the recombinant DNA molecules are transformed into a host cell such as E. coli. Transformants are screened for by, for example, blue-white screening, as is known in the art. After identification of a recombinant vector containing the appropriate insert by for example, restriction digest analysis and/or nucleotide sequence analysis, the recombinant neurotoxin is expressed using either a constituitive or inducible promoter depending on the type of expression vector used. The recombinant protein produced by the expression system can be isolated using conventional techniques. For example, if an expression vector which produces a polyhis-factor Xa fusion protein is used, the protein can be first isolated on a metal containing column, such as a nickel, and then cleaved with factor Xa to release the neurotoxin molecule. Many variations for producing neurotoxins by recombinant methodologies exist and are familiar to those skilled in the art. For example, yeast, mammalian or insect cell systems may be used to produce recombinant neurotoxin proteins.

[0115] The recombinant protein may comprise all three components of the neurotoxin. For example, the protein expressed may include a light chain of botulinum toxin type E (the therapeutic component), a heavy chain, preferably the H.sub.N, of a botulinum toxin type B (the translocation component), and an H.sub.C of botulinum toxin type A, which selectively binds to the motor neurons. In one embodiment, the protein expressed may include less than all three components of the neurotoxin. In such case, the components may be chemically joined using techniques known in the art.

[0116] There are many advantages to producing these neurotoxins recombinantly. For example, production of neurotoxin from anaerobic Clostridium cultures is a cumbersome and time-consuming process including a multi-step purification protocol involving several protein precipitation steps and either prolonged and repeated crystallization of the toxin or several stages of column chromatography. Significantly, the high toxicity of the product dictates that the procedure must be performed under strict containment (BL-3). During the fermentation process, the folded single-chain neurotoxins are activated by endogenous Clostridial proteases through a process termed nicking. This involves the removal of approximately 10 amino acid residues from the single-chain to create the di-chain form in which the two chains remain covalently linked through the intrachain disulfide bond.

[0117] The nicked neurotoxin is much more active than the unnicked form. The amount and precise location of nicking varies with the serotypes of the bacteria producing the toxin. The differences in single-chain neurotoxin activation and, hence, the yield of nicked toxin, are due to variations in the type and amounts of proteolytic activity produced by a given strain. For example, greater than 99% of Clostridial botulinum type A single-chain neurotoxin is activated by the Hall A Clostridial botulinum strain, whereas type B and E strains produce toxins with lower amounts of activation (0 to 75% depending upon the fermentation time). Thus, the high toxicity of the mature neurotoxin plays a major part in the commercial manufacture of neurotoxins as therapeutic neurotoxins.

[0118] The degree of activation of engineered Clostridial toxins is, therefore, an important consideration for manufacture of these materials. It would be a major advantage if neurotoxins such as botulinum toxin and tetanus toxin could be expressed, recombinantly, in high yield in rapidly-growing bacteria (such as heterologous E. coli cells) as relatively non-toxic single-chains (or single chains having reduced toxic activity) which are safe, easy to isolate and simple to convert to the fully-active form.

[0119] With safety being a prime concern, previous work has concentrated on the expression in E. coli and purification of individual H and L chains of tetanus and botulinum toxins; these isolated chains are, by themselves, non-toxic; see Li et al., Biochemistry 33:7014-7020 (1994); Zhou et al., Biochemistry 34:15175-15181 (1995), hereby incorporated by reference herein. Following the separate production of these peptide chains and under strictly controlled conditions the H and L subunits can be combined by oxidative disulphide linkage to form the neuroparalytic di-chains.

[0120] In another embodiment, a DNA nucleotide sequence encoding a neurotoxin is injected into an animal or human subject. For example, the DNA nucleotide sequence may be that of botulinum toxin type A (SEQ. ID. #1), type B (SEQ. ID. #2 and #3), type C.sub.1 (SEQ. ID #4), type D (SEQ. ID. #5), type E (SEQ. ID. #6 and #7), type F (SEQ. ID. #8) and type G (SEQ. ID. #9), variants thereof or fragments thereof. In one embodiment, the injected DNA nucleotide sequence encodes a Clostridial toxin or a variant of a Clostridial toxin. In one embodiment the nucleotide sequence encodes a botulinum toxin type A. In another embodiment the DNA nucleotide sequence encodes a fragment of a neurotoxin. For example, the DNA sequence may encode a therapeutic component, for example, a light chain of a botulinum toxin.

[0121] Injection of the DNA nucleotide sequence may be, for example, to treat a condition in an animal, for example a human. Injection of a DNA nucleotide sequence encoding a Clostridial toxin may also be used to immunize an animal or human subject.

[0122] Injection of the DNA nucleotide sequence may also be used for research purposes. For example, these methods may be used to examine the expression of Clostridial genes inside an animal cell in situ. Also, for example, activity of a neurotoxin inside of an animal cell in situ may be studied using these methods.

[0123] A neurotoxin or DNA sequence encoding a neurotoxin may be injected alone, or in combination with other drugs and/or agents. In either case, the neurotoxin or DNA sequence encoding a neurotoxin may be prepared as pharmaceutical compositions. The composition may contain one or more added materials such as carriers and/or excipients. As used herein, "carriers" and "excipients" generally refer to substantially inert, non-toxic materials that do not deleteriously interact with other components of the composition. These materials may be used to increase the amount of solids in particulate pharmaceutical compositions, such as to form a powder of drug particles suitable for use with a needleless injector. Examples of suitable carriers include water, silicone, gelatin, waxes, and the like. Although a naked DNA nucleotide sequence may be injected in accordance with this invention, it is preferable that the injected DNA be accompanied by a carrier, for example See Felgner et al, U.S. Pat. No. 5,459,127, the disclosure of which is incorporated in its entirety herein by reference.

[0124] Other suitable carriers include any high density, biologically inert materials. For example, tungsten, platinum, iridium gold and/or ice crystal may be employed as carriers. In one embodiment, the carrier is less than about 10 mm, more preferably less than about 5 mm, even more preferably less than about 3 mm. High density carriers of such size may readily enter living cells without unduly injuring such cells. In one embodiment, a drug particle comprises a neurotoxin, for example botulinum toxin type A, and a carrier, for example a high density material of less than 5 mm, wherein the neurotoxin protein is coated onto the high density carrier using techniques commonly known in the art. Ice crystals and gold are preferred carriers of this invention. Ice crystal particles are readily available in average sizes of 0.5 to 2.0 mm in diameter and are thus suited for intracellular delivery. Gold is also a preferred carrier, since gold has a high density and is relatively inert to biological materials and resists oxidation. Moreover, gold is readily available in the form of spheres having an average diameter of from about 0.2 to about 3 mm. In one embodiment, neurotoxin is coated onto ice crystal and/or gold carriers to form drug particles. In a another embodiment, botulinum toxin type A is coated onto ice crystals and/or gold carriers to form drug particles to be used in accordance with this invention.

[0125] Examples of normally employed "excipients," include pharmaceutical grades of mannitol, sorbitol, inositol, dextrose, sucrose, lactose, trehalose, dextran, starch, cellulose, sodium or calcium phosphates, calcium sulfate, citric acid, tartaric acid, glycine, high molecular weight polyethylene glycols (PEG), and the like and combinations thereof. In one embodiment, the excipient may also include a charged lipid and/or detergent in the pharmaceutical compositions. Suitable charged lipids include, without limitation, phosphatidylcholines (lecithin), and the like. Detergents will typically be a nonionic, anionic, cationic or amphoteric surfactant. Examples of suitable surfactants include, for example, Tergitol.RTM. and Triton.RTM. surfactants (Union Carbide Chemicals and Plastics, Danbury, Conn.), polyoxyethylenesorbitans, for example, TWEEN.RTM. surfactants (Atlas Chemical Industries, Wilmington, Del.), polyoxyethylene ethers, for example, Brij.RTM., pharmaceutically acceptable fatty acid esters, for example, lauryl sulfate and salts thereof (SDS), and the like. Such materials may be used as stabilizers and/or anti-oxidants. Additionally, they may be used to reduce local irritation at the site of administration.

[0126] In one broad embodiment, the step of administering a neurotoxin or DNA sequence encoding a neurotoxin according to the present invention may include other steps. These other steps may be carried out before, in conjunction with, and/or after the step of administering the drug particle according to the invention. In one embodiment, these other steps may include applying topical medications, for example aluminum chloride; applying an iontophoresis procedure; and/or administering anticholinergics orally or systemically.

[0127] The following examples demonstrate how various conditions may be treated according to the present invention. Although particular doses are described, the dose administered can vary widely according to the severity of the condition and other various subject variables including size, weight, age, and responsiveness to therapy.

[0128] The examples also show how a neurotoxin or components thereof may be recombinantly synthesized and reconstituted. The examples relating to recombinant synthesis are substantially similar to the Examples of International Patent Application Publication WO 95/32738, the disclosure of which is incorporated in its entirety herein by reference.

EXAMPLE 1

Treatment of Post Surgical Myofacial Pain Syndrome

[0129] An unfortunate 36 year old woman has a 15 year history of temporomandibular joint disease and chronic pain along the masseter and temporalis muscles. Fifteen years prior to evaluation she noted increased immobility of the jaw associated with pain and jaw opening and closing and tenderness along each side of her face. The left side is originally thought to be worse than the right. She is diagnosed as having temporomandibular joint (TMJ) dysfunction with subluxation of the joint and is treated with surgical orthoplasty meniscusectomy and condyle resection.

[0130] She continues to have difficulty with opening and closing her jaw after the surgical procedures and for this reason, several years later, a surgical procedure to replace prosthetic joints on both sides is performed. After the surgical procedure, progressive spasms and deviation of the jaw ensues. Further surgical revision is performed subsequent to the original operation to correct prosthetic joint loosening. The jaw continues to exhibit considerable pain and immobility after these surgical procedures. The TMJ remained tender as well as the muscle itself. There are tender points over the temporomandibular joint as well as increased tone in the entire muscle. She is diagnosed as having post-surgical myofascial pain syndrome and is treated with a needleless injection of 20 U of botulinum type A neurotoxin into the skin covering the masseter and temporalis muscles.

[0131] Several days after the injections she noted substantial improvement in her pain and reports that her jaw feels looser. This gradually improves over a 2 to 3 week period in which she notes increased ability to open the jaw and diminishing pain. The patient states that the pain is better than at any time in the last 4 years. The improved condition persists for up to 27 months after the original injection of the modified neurotoxin.

EXAMPLE 2

Peripheral Administration of a Modified Neurotoxin to Treat "Shoulder-Hand Syndrome"

[0132] Pain in the shoulder, arm, and hand can develop, with muscular dystrophy, osteoporosis, and fixation of joints. While most common after coronary insufficiency, this syndrome may occur with cervical osteoarthritis or localized shoulder disease, or after any prolonged illness that requires the patient to remain in bed.

[0133] A 46 year old woman presents a shoulder-hand syndrome type pain. The pain is particularly localized at the deltoid region. The patient is treated by a needleless injection of between about 0.05 U/kg to about 2 U/kg of a modified neurotoxin cutaneously to the shoulder, preferably the neurotoxin is botulinum type A. The particular dose as well as the frequency of administrations depends upon a variety of factors within the skill of the treating physician, as previously set forth. Within 1-7 days after modified neurotoxin administration the patient's pain is substantially alleviated. The duration of the pain alleviation is from about 7 to about 27 months.

EXAMPLE 3

Peripheral Administration of a Modified Neurotoxin to Treat Postherpetic Neuralgia

[0134] Postherpetic neuralgia is one of the most intractable of chronic pain problems. Patients suffering this excruciatingly painful process often are elderly, have debilitating disease, and are not suitable for major interventional procedures. The diagnosis is readily made by the appearance of the healed lesions of herpes and by the patient's history. The pain is intense and emotionally distressing. Postherpetic neuralgia may occur any where, but is most often in the thorax.

[0135] A 76 year old man presents a postherpetic type pain.

[0136] The pain is localized to the abdomen region. The patient is treated by a needleless injection of between about 0.05 U/kg to about 2 U/kg of a modified neurotoxin intradermally to the abdomen, preferably the modified neurotoxin is BoNT/E fused with a leucine-based motif. The particular dose as well as the frequency of administrations depends upon a variety of factors within the skill of the treating physician, as previously set forth. Within 1-7 days after modified neurotoxin administration the patient's pain is substantially alleviated. The duration of the pain alleviation is from about 7 to about 27 months.

EXAMPLE 4

Peripheral Administration of a Modified Neurotoxin to Treat Inflammatory Pain

[0137] A patient, age 45, presents an inflammatory pain in the chest region. The patient is treated by a needleless injection of between about 0.05 U/kg to about 2 U/kg of a botulinum neurotoxin type A intramuscularly to the chest. The particular dose as well as the frequency of administrations depends upon a variety of factors within the skill of the treating physician, as previously set forth. Within 1-7 days after modified neurotoxin administration the patient's pain is substantially alleviated. The duration of the pain alleviation is from about 7 to about 27 months.

EXAMPLE 5

{tc "Example 5"\l 4} Local Administration of a Neurotoxin to Treat Pain Caused by Bone Fractures {tc "Local Administration of a Neurotoxin to Treat Pain Caused by Bone Fractures" \l 3}

[0138] A patient, age 40, suffering from cervical dystonia is treated by an needleless injection of a neurotoxin, preferably botulinum toxin type A, at the effected area of the spine. The amount of neurotoxin injected is between about 20 U to about 500 U. The particular dose as well as the frequency of administrations depends upon a variety of factors within the skill of the treating physician, as previously set forth. Within 1-7 days after administration the patient's pain is substantially alleviated. The duration of pain reduction is from about 2 to about 7 months.

EXAMPLE 6

Treatment of Pain Associated with Muscle Disorder

[0139] An unfortunate 36 year old woman has a 15 year history of temporomandibular joint disease and chronic pain along the masseter and temporalis muscles. Fifteen years prior to evaluation she noted increased immobility of the jaw associated with pain and jaw opening and closing and tenderness along each side of her face. The left side is originally thought to be worse than the right. She is diagnosed as having temporomandibular joint (TMJ) dysfunction with subluxation of the joint and is treated with surgical orthoplasty meniscusectomy and condyle resection.

[0140] She continues to have difficulty with opening and closing her jaw after the surgical procedures and for this reason, several years later, a surgical procedure to replace prosthetic joints on both sides is performed. After the surgical procedure progressive spasms and deviation of the jaw ensues. Further surgical revision is performed subsequent to the original operation to correct prosthetic joint loosening. The jaw continues to exhibit considerable pain and immobility after these surgical procedures. The TMJ remained tender as well as the muscle itself. There are tender points over the temporomandibular joint as well as increased tone in the entire muscle. She is diagnosed as having post-surgical myofascial pain syndrome and is treated with a needleless injection of 15 U of botulinum toxin type A into the masseter and temporalis muscles.

[0141] Several days after the injections she noted substantial improvement in her pain and reports that her jaw feels looser. This gradually improves over a 2 to 3 week period in which she notes increased ability to open the jaw and diminishing pain. The patient states that the pain is better than at any time in the last 4 years. The improved condition persists for up to 27 months after the original injection of the modified neurotoxin.

EXAMPLE 7

Treatment of Pain Subsequent to Spinal Cord Injury

[0142] A patient, age 39, experiencing pain spasticity of the right side bicep muscle is treated by needleless injection with about 1.0 U/kg of the modified neurotoxin, preferably the modified neurotoxin is botulinum toxin type A. The particular toxin dose and site of injection, as well as the frequency of toxin administrations depend upon a variety of factors within the skill of the treating physician, as previously set forth. Within about 1 to about 7 days after the modified neurotoxin administration, the patient's muscle spasms are substantially reduced. The spasm alleviation persists for up to 27 months.

EXAMPLE 8

Peripheral Administration of a Modified Neurotoxin to Treat "Shoulder-Hand Syndrome"

[0143] A 46 year old woman presents a shoulder-hand syndrome type pain. The pain is particularly localized at the deltoid region. The patient is treated by a needleless injection of between about 0.05 U/kg to about 2 U/kg of botulinum type A neurotoxin subcutaneously to the shoulder. The particular dose as well as the frequency of administrations depends upon a variety of factors within the skill of the treating physician, as previously set forth. Within 1-7 days after modified neurotoxin administration the patient's pain is substantially alleviated. The duration of the pain alleviation is from about 7 to about 27 months.

EXAMPLE 9

Treatment of Axillary Hyperhidrosis

[0144] Axillary hyperhidrosis is a condition which may be socially and emotionally disturbing. It is a condition of excessive sweating, which may even cause staining and decaying of clothes. Initially, the treatment usually consists of topical application of antiperspirants containing aluminium salts and/or tanning agents. Iontophoresis using special axillary electrodes are also employed in the treatment of axillary hyperhidrosis. Oral sedatives, tranquilizers or anticholinergic drugs are sometimes used as an adjunct.

[0145] If the medical treatment proves ineffective or produces unacceptable side-effect, removal of the axillary sweat glands by surgical excision or liposuction is the other current option. Surgery and liposuction, although often effective in controlling excessive sweating, are commonly complicated by infection, bleeding, scarring, loss of axillary hair, hypoaesthesia, pain due to nerve injury or entrapment and, occasionally, reinnervation of the residual glands and recurrence of hyperhidrosis. Denervation of sweat glands by sympathectomy is also effective but carries the risk of pneumothorax, Homer's syndrome and other complications.

[0146] A 35 year old office female dancer presents with a severe case of axillary hyperhidrosis. The area of hyperhidrosis under the forearm is visualized by means of an iodinestarch solution (Minor's iodine-starch test) The hyperhidrosis area is then marked with a pen.

[0147] Botulinum toxin type A coated on crystal ice particle carrier is loaded into a needleless injector.

[0148] The projection pressure is set so that the drug particles, i.e., the botulinum toxin A coated ice crystal particles, may be delivered to the dermis layer of the skin. Also, such an amount of the drug particle is loaded so that about 20 U to about 60 of botulinum toxin type A is delivered to 8.times.15 cm.sup.2 of the demarcated skin area. The particular dose of the neurotoxin and area of injection, as well as the frequency of toxin administrations depend upon a variety of factors to be determined by the treating physician, as previously set forth.

[0149] Two weeks after treatment, the axillary sweating response is measured using the Minor's iodine test. The hyperhidrotic area shows about a 95% reduction. The reduction in axillary sweating remains up to about 27 months, preferably 11 months.

EXAMPLE 10

Treatment of Palmar Hyperhidrosis

[0150] Botulinum toxin has been injected into the palmar area to treat palmar hyperhidrosis, and has been found to be very effective. However, one of the main drawback of this treatment is the pain cause by the injection. The free nerve endings responsible for the pain sensation occur in the papillarv dermis and epidermis whereas the sweat glands are imbedded deep in the dermis and in the upper layer of the subcutaneous tissue. To deliver the botulinum toxin as close to the sweat glands as possible, subdermal/subcutaneous injections would be optimal, and presumably less painful than more superficial injections. However, the deeper the injection the greater the risk of causing weakness of the small muscles of the hand and weakening the grip.

[0151] A 22 year old concert pianist presents with a palmar hyperhidrosis. The specific area of hyperhidrosis on the hand is visualized by means of an iodinestarch solution (Minor's iodine-starch test). The hyperhidrosis area is then marked with a pen.

[0152] Botulinum toxin type A coated on crystal ice particle carrier is loaded into a needleless injector.

[0153] The projection pressure is set so that the drug particles, i.e., the botulinum toxin A coated ice crystal particles, may be delivered to the dermis layer of the skin. Also, such amount of the drug particle is loaded so that about 10 U to about 50 U of botulinum toxin type A is delivered to 10.times.15 cm.sup.2 of the demarcated skin area. An effective therapeutic dose of botulinum toxin is injected without substantial pain. Additionally, no substantial muscle weakness or fatigue of the hand is observed. The particular dose of the neurotoxin and area of injection, as well as the frequency of toxin administrations depend upon a variety of factors to be determined by the treating physician, as previously set forth.

[0154] Two weeks after treatment, the reduced sweating response is measured in the area of hyperhidrosis using the Minor's iodine test. The hyperhidrotic area shows about a 95% reduction. The reduction in sweating remains up to about 12 months.

EXAMPLE 11

Subcloning the BoNT/A-L Chain Gene

[0155] This Example describes the methods to clone the polynucleotide sequence encoding the BoNT/A-L chain. The DNA sequence encoding the BoNT/A-L chain is amplified by a PCR protocol that employs synthetic oligonucleotides having the sequences, 5'-AAAGGCCTTTTGTTAATAAACAA-3' (SEQ ID#10) and 5'-GGAATTCTTACTTATTGTATCCTTTA-3' (SEQ ID#11). Use of these primers allows the introduction of Stu I and EcoR I restriction sites into the 5' and 3' ends of the BoNT/A-L chain gene fragment, respectively. These restriction sites are subsequently used to facilitate unidirectional subcloning of the amplification products.

[0156] Additionally, these primers introduce a stop codon at the C-terminus of the L chain coding sequence. Chromosomal DNA from C. botulinum (strain 63 A) serves as a template in the amplification reaction.

[0157] The PCR amplification is performed in a 100 ml volume containing 10 mM Tris-HCI (pH 8.3), 50 mM KCl, 1.5 mM MgCI.sub.2, 0.2 mM of each deoxynucleotide triphosphate (dNTP), 50 .mu.mol of each primer, 200 ng of genomic DNA and 2.5 units of Taq-polymerase (Promega). The reaction mixture is patiented to 35 cycles of denaturation (1 minute at 94.degree. C.), annealing (2 minutes at 37.degree. C.) and polymerization (2 minutes at 72.degree. C.). Finally, the reaction is extended for an additional 5 minutes at 72.degree. C.

[0158] The PCR amplification product is digested with Stu I and EcoR I, purified by agarose gel electrophoresis, and ligated into Sma I and EcoR I digested pBluescript II SK* to yield the plasmid, pSAL. Bacterial transformants harboring this plasmid are isolated by standard procedures. The identity of the cloned L chain polynucleotide is confirmed by double stranded plasmid sequencing using SEQUENASE (United States Biochemicals) according to the manufacturer's instructions. Synthetic oligonucleotide sequencing primers are prepared as necessary to achieve overlapping sequencing runs. The cloned sequence is found to be identical to the sequence disclosed by Binz, et al., in J. Biol. Chem. 265:9153 (1990), and Thompson et al., in Eur. J. Biochem. 189:73 (1990).

[0159] Site-directed mutants designed to compromise the enzymatic activity of the BoNT/A-L chain can also be created.

EXAMPLE 12

Expression of the Botulinum Toxin Type A-L (BoNt/A-L) Chain Fusion Proteins

[0160] This Example describes the methods to verify expression of the wild-type L chains, which may serve as a therapeutic component, in bacteria harboring the pCA-L plasmids. Well isolated bacterial colonies harboring either pCAL are used to inoculate L-broth containing 100 mg/ml ampicillin and 2% (w/v) glucose, and grown overnight with shaking at 30.degree. C. The overnight cultures are diluted 1:10 into fresh L-broth containing 100 mg/ml of ampicillin and incubated for 2 hours. Fusion protein expression is induced by addition of IPTG to a final concentration of 0.1 mM. After an additional 4 hour incubation at 30.degree. C., bacteria are collected by centrifugation at 6,000.times.g for 10 minutes.

[0161] A small-scale SDS-PAGE analysis confirmed the presence of a 90 kDa protein band in samples derived from IPTG-induced bacteria. This M.sub.r is consistent with the predicted size of a fusion protein having MBP (.about.40 kDa) and BoNT/A-L chain (.about.50 kDa) components. Furthermore, when compared with samples isolated from control cultures, the IPTG-induced clones contained substantially larger amounts of the fusion protein.

[0162] The presence of the desired fusion proteins in IPTG-induced bacterial extracts is also confirmed by Western blotting using the polyclonal anti-L chain probe described by Cenci di Bello et al., in Eur. J. Biochem. 219:161 (1993). Reactive bands on PVDF membranes (Pharmacia; Milton Keynes, UK) are visualized using an anti-rabbit immunoglobulin conjugated to horseradish peroxidase (Bio-Rad; Hemel Hempstead, UK) and the ECL detection system (Amersham, UK). Western blotting results confirmed the presence of the dominant fusion protein together with several faint bands corresponding to proteins of lower M.sub.r than the fully sized fusion protein. This observation suggested that limited degradation of the fusion protein occurred in the bacteria or during the isolation procedure. Neither the use of 1 mM nor 10 mM benzamidine (Sigma; Poole, UK) during the isolation procedure eliminated this proteolytic breakdown.

[0163] The yield of intact fusion protein isolated by the above procedure remained fully adequate for all procedures described herein. Based on estimates from stained SDS-PAGE gels, the bacterial clones induced with IPTG yielded 5-10 mg of total MBP-wild-type or mutant L chain fusion protein per liter of culture. Thus, the method of producing BoNT/A-L chain fusion proteins disclosed herein is highly efficient, despite any limited proteolysis that did occur.

[0164] The MBP-L chain fusion proteins encoded by the pCAL and pCAL-TyrU7 expression plasmids are purified from bacteria by amylose affinity chromatography. Recombinant wild-type or mutant L chains are then separated from the sugar binding domains of the fusion proteins by site-specific cleavage with Factor Xa. This cleavage procedure yielded free MBP, free L chains and a small amount of uncleaved fusion protein. While the resulting L chains present in such mixtures have been shown to possess the desired activities, we have also employed an additional purification step. Accordingly, the mixture of cleavage products is applied to a second amylose affinity column that bound both the MBP and uncleaved fusion protein. Free L chains are not retained on the affinity column, and are isolated for use in experiments described below.

EXAMPLE 13

Purification of Fusion Proteins and Isolation of Recombinant BoNT/A-L Chains

[0165] This Example describes a method to produce and purify wild-type recombinant BoNT/A light chains from bacterial clones. Pellets from 1 liter cultures of bacteria expressing the wild-type BoNT/A-L chain proteins are resuspended in column buffer [10 mM Tris-HCI (pH 8.0), 200 mM NaCl, 1 mM EGTA and I mM DTT] containing 1 mM phenyl-methanesulfonyl fluoride (PMSF) and 10 mM benzamidine, and lysed by sonication. The lysates are cleared by centrifugation at 15,000.times.g for 15 minutes at 4.degree. C. Supernatants are applied to an amylose affinity column [2.times.10 cm, 30 ml resin] (New England BioLabs; Hitchin, UK). Unbound proteins are washed from the resin with column buffer until the eluate is free of protein as judged by a stable absorbance reading at 280 nm. The bound MBP-L chain fusion protein is subsequently eluted with column buffer containing 10 mM maltose. Fractions containing the fusion protein are pooled and dialyzed against 20 mM Tris-HCI (pH 8.0) supplemented with 150 mM NaCl, 2 mM, CaCl.sub.2 and 1 mM DTT for 72 hours at 4.degree. C.

[0166] Fusion proteins are cleaved with Factor X.sub.2 (Promega; Southampton, UK) at an enzyme:substrate ratio of 1:100 while dialyzing against a buffer of 20 mM Tris-HCl (pH 8.0) supplemented with 150 mM NaCl, 2 mM, CaCl.sub.2 and 1 mM DTT. Dialysis is carried out for 24 hours at 4.degree. C. The mixture of MBP and either wild-type or mutant L chain that resulted from the cleavage step is loaded onto a 10 ml amylose column equilibrated with column buffer. Aliquots of the flow through fractions are prepared for SDS-PAGE analysis to identify samples containing the L chains. Remaining portions of the flow through fractions are stored at -20.degree. C. Total E. coli extract or the purified proteins are solubilized in SDS sample buffer and patiented to PAGE according to standard procedures. Results of this procedure indicated the recombinant toxin fragment accounted for roughly 90% of the protein content of the sample.

[0167] The foregoing results indicates that the approach to creating MBP-L chain fusion proteins described herein could be used to efficiently produce wild-type and mutant recombinant BoNT/A-L chains. Further, the results demonstrate that recombinant L chains could be separated from the maltose binding domains of the fusion proteins and purified thereafter.

[0168] A sensitive antibody-based assay is developed to compare the enzymatic activities of recombinant L chain products and their native counterparts. The assay employed an antibody having specificity for the intact C-terminal region of SNAP-25 that corresponded to the BoNT/A cleavage site. Western Blotting of the reaction products of BoNT/A cleavage of SNAP-25 indicated an inability of the antibody to bind SNAP-25 sub-fragments. Thus, the antibody reagent employed in the following Example detected only intact SNAP-25. The loss of antibody binding served as an indicator of SNAP-25 proteolysis mediated by added BoNT/A light chain or recombinant derivatives thereof.

EXAMPLE 14

Evaluation of the Proteolytic Activities of Recombinant L Chains Against a SNAP-25 Substrate

[0169] This Example describes a method to demonstrate that both native and recombinant BoNT/A-L chains can proteolyze a SNAP-25 substrate. A quantitative assay is employed to compare the abilities of the wild-type and their recombinant analogs to cleave a SNAP-25 substrate. The substrate utilized for this assay is obtained by preparing a glutathione-S-transferase (GST)-SNAP-25 fusion protein, containing a cleavage site for thrombin, expressed using the pGEX-2T vector and purified by affinity chromatography on glutathione agarose. The SNAP-25 is then cleaved from the fusion protein using thrombin in 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCI and 2.5 mM CaCI.sub.2 (Smith et al., Gene 67:31 (1988)) at an enzyme:substrate ratio of 1:100. Uncleaved fusion protein and the cleaved glutathione-binding domain bound to the gel. The recombinant SNAP-25 protein is eluted with the latter buffer and dialyzed against 100 mM HEPES (pH 7.5) for 24 hours at 4.degree. C. The total protein concentration is determined by routine methods.

[0170] Rabbit polyclonal antibodies specific for the C-terminal region of SNAP-25 are raised against a synthetic peptide having the amino acid sequence, CANQRATKMLGSG (SEQ ID#12). This peptide corresponded to residues 195 to 206 of the synaptic plasma membrane protein and an N-terminal cysteine residue not found in native SNAP-25. The synthetic peptide is conjugated to bovine serum albumin (BSA) (Sigma; Poole, UK) using maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) as a cross-linking agent (Sigma; Poole, UK) to improve antigenicity (Liu et al., Biochemistry 18:690 (1979)1. Affinity purification of the anti-peptide antibodies is carried out using a column having the antigenic peptide conjugated via its N-terminal cysteine residue to an aminoalkyl agarose resin (Bio-Rad; Hemel Hempstead, UK), activated with iodoacetic acid using the cross-linker ethyl 3-(3-dimethylpropyl) carbodiimide. After successive washes of the column with a buffer containing 25 mM Tris-HCl (pH 7.4) and 150 mM NaCl, the peptide-specific antibodies are eluted using a solution of 100 mM glycine (pH 2.5) and 200 mM NaCl, and collected in tubes containing 0.2 ml of 1 M Tris-HCl (pH 8.0) neutralizing buffer.

[0171] All recombinant preparations containing wild-type L chain are dialyzed overnight at 4.degree. C. into 100 mM HEPES (pH 7.5) containing 0.02% Lubrol and 10 mM zinc acetate before assessing their enzymatic activities. BoNT/A, previously reduced with 20 mM DTT for 30 minutes at 37.degree. C., as well as these dialyzed samples, are then diluted to different concentrations in the latter HEPES buffer supplemented with 1 mM DTT.

[0172] Reaction mixtures include 5 ml recombinant SNAP-25 substrate (8.5 mM final concentration) and either 20 ml reduced BoNT/A or recombinant wild-type L chain. All samples are incubated at 37.degree. C. for 1 hour before quenching the reactions with 25 ml aqueous 2% trifluoroacetic acid (TFA) and 5 mM EDTA (Foran et al., Biochemistry 33:15365 (1994)). Aliquots of each sample are prepared for SDS-PAGE and Western blotting with the polyclonal SNAP-25 antibody by adding SDS-PAGE sample buffer and boiling. Anti-SNAP-25 antibody reactivity is monitored using an ECL detection system and quantified by densitometric scanning.

[0173] Western blotting results indicate clear differences between the proteolytic activities of the purified mutant L chain and either native or recombinant wild-type BoNT/A-L chain. Specifically, recombinant wild-type L chain cleaves the SNAP-25 substrate, though somewhat less efficiently than the reduced BoNT/A native L chain that serves as the positive control in the procedure. Thus, an enzymatically active form of the BoNT/A-L chain is produced by recombinant means and subsequently isolated. Moreover, substitution of a single amino acid in the L chain protein abrogated the ability of the recombinant protein to degrade the synaptic terminal protein.

[0174] As a preliminary test of the biological activity of the wild-type recombinant BoNT/A-L chain, the ability of the MBP-L chain fusion protein to diminish Ca.sup.2+-evoked catecholamine release from digitonin-permeabilized bovine adrenochromaffin cells is examined. Consistently, wild-type recombinant L chain fusion protein, either intact or cleaved with Factor X.sub.2 to produce a mixture containing free MBP and recombinant L chain, induced a dose-dependent inhibition of Ca.sup.2+-stimulated release equivalent to the inhibition caused by native BoNT/A.

EXAMPLE 15

Reconstitution of Native L Chain, Recombinant Wild-Type L Chain with Purified H Chain

[0175] Native H and L chains are dissociated from BoNT/A (List Biologicals Inc.; Campbell, USA) with 2 M urea, reduced with 100 mM DTT and then purified according to established chromatographic procedures (Kozaki et al., Japan J. Med. Sci. Biol. 34:61 (1981); Maisey et al., Eur. J. Biochem. 177:683 (1988)). Purified H chain is combined with an equimolar amount of either native L chain or recombinant wild-type L chain. Reconstitution is carried out by dialyzing the samples against a buffer consisting of 25 mM Tris (pH 8.0), 50 mM zinc acetate and 150 mM NaCl over 4 days at 4.degree. C. Following dialysis, the association of the recombinant L chain and native H chain to form disulfide-linked 150 kDa di-chains is monitored by SDS-PAGE and quantified by densitometric scanning. The proportion of di-chain molecules formed with the recombinant L chains is lower than that obtained when native L chain is employed. Indeed, only about 30% of the recombinant wild-type or mutant L chain is reconstituted while >90% of the native L chain reassociated with the H chain. In spite of this lower efficiency of reconstitution, sufficient material incorporating the recombinant L chains is easily produced for use in subsequent functional studies.

EXAMPLE 16

A Study of Botulinum Neurotoxin Type A Activity When the Toxin is Produced in Skin and Muscle cells of an Animal

[0176] Genes encoding botulinum toxin type A are expressed in the skin and muscle cells of live mice in situ by needleless injection of DNA coated microprojectiles into the tissues.

[0177] The DNA encoding recombinant botulinum toxin comprises two nucleotide sequences. One sequence contains a human beta-actin promoter fused to a DNA sequence encoding the heavy chain of botulinum type A. The second sequence contains a human beta-actin promoter fused to a DNA sequence encoding a light chain of botulinum toxin. Polyadenylation signal sequences are added 3' to the Clostridium genes. Stop codons are placed at the 5' end of each gene to allow translation of the complete heavy chain and light chains.

[0178] Substance particles, for example, gold particles or tungsten particles, having a range of diameter from 1 to 3 micrometers or 2 to 5 micrometers are coated with DNA by mixing sequentially 25 microliters of gold or tungsten microprojectiles in an aqueous slurry, 2.5 microliters of DNA (1 mg/ml), 25 microliters of CaCl.sub.2 and 5 microliters of free base spermidine (1M). After 10 min of incubation, the microprojectiles are collected by centrifugation and the supernatant removed. The pellet is washed once in 70% ethanol, centrifuged and resuspended in 25 microliters of 100% ethanol. The ethanol is allowed to evaporate from the DNA coated microprojectiles before injection.

[0179] The DNA coated microprojectiles are administered into the skin, or into the skin and underlying muscle tissue of the mice by needleless injection.

[0180] Botulinum toxin gene expression is assessed by, for example, in situ hybridization. In situ hybridization is performed 24 hours after the injection. The muscle and skin tissues are frozen and cryosectioned at 10-micrometer thickness. The sections are dried onto gelatin/chrom alum-coated slides, fixed with 4% paraformaldehyde and hybridized with .sup.35S-labeled synthetic oligonucleotide probes complementary to the botulinum toxin mRNAs. FITC labeled antibodies to the heavy and light chains were also used as probes. Results showed 10 to 20% of the skin cells in the area of injection expressed the botulinum toxin genes. While 5 to 10% of the muscle cells in the injection area expressed the genes.

[0181] In mice where the DNA coated particles were administered to the skin and substantially to underlying muscle tissue, a partial paralysis of the effected muscle was noted.

EXAMPLE 17

Peripheral Administration of a Modified Neurotoxin DNA Encoding Sequence to Treat Inflammatory Pain

[0182] A patient, age 45, presents a case of blepharospasm. The patient is treated by a needleless injection to the skin near the eye of between about 10 nanograms to about 5 micrograms of DNA encoding botulinum neurotoxin plus appropriate flanking sequences, preferably the neurotoxin is type A. Preferably, gold or tungsten microprojectiles are coated with the DNA. The particular dose as well as the frequency of administration depends upon a variety of factors within the skill of the treating physician. Within 1-7 days after modified neurotoxin administration the patient's pain is substantially alleviated. The duration of the alleviation of spasmotic winking is from about 7 to about 27 months.

EXAMPLE 18

Treatment of Gustatory Sweating

[0183] Gustatory sweating (Frey's syndrome, auriculotemporal syndrome) is sweating of the facial skin during meals and commonly is seen following parotid gland surgery and trauma to the preauricular region. Denervated sweat glands become reinnervated by misdirected sprouting of parasympathetic secretomotor fibers that have lost their "target organ," the salivary gland. Gustatory sweating is experienced by 13-50% of patients after pariodectomy.

[0184] A 40 year old man presents a classic case of Frey's syndrome. The area of hyperhydrosis on the face is visualized by means of an iodinestarch solution (Minor's iodine-starch test) after sweating is stimulated by having the patient chew an apple or sour fruit candy. The hyperhidrosis area is then marked with a pen.

[0185] DNA encoding botulinum toxin type A and appropriate flanking sequences, i.e. transcription initiation and termination sequences, is coated on a gold particle carrier. The coated carrier is loaded into a needleless injector. The projection pressure is set so that the drug particles may be delivered to the dermis layer of the skin. The particular dose of the neurotoxin DNA and area of injection, as well as the frequency of toxin administration depends upon a variety of factors to be determined by the treating physician, as previously set forth.

[0186] Seven days after treatment, the gustatory sweating is measured using the Minor's iodine test. The hyperhidrotic area shows about 93% reduction. The reduction in gustatory sweating starts after about 72 hours and persists up to about 12 months.

[0187] While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced with the scope of the following claims. Other embodiments, versions, and modifications within the scope of the present invention are possible.

Sequence CWU 1

1

1213891DNAbotulinum toxin 1atgcaatttg ttaataaaca atttaattat aaagatcctg taaatggtgt tgatattgct 60tatataaaaa ttccaaatgt aggacaaatg caaccagtaa aagcttttaa aattcataat 120aaaatatggg ttattccaga aagagataca tttacaaatc ctgaagaagg agatttaaat 180ccaccaccag aagcaaaaca agttccagtt tcatattatg attcaacata tttaagtaca 240gataatgaaa aagataatta tttaaaggga gttacaaaat tatttgagag aatttattca 300actgatcttg gaagaatgtt gttaacatca atagtaaggg gaataccatt ttggggtgga 360agtacaatag atacagaatt aaaagttatt gatactaatt gtattaatgt gatacaacca 420gatggtagtt atagatcaga agaacttaat ctagtaataa taggaccctc agctgatatt 480atacagtttg aatgtaaaag ctttggacat gaagttttga atcttacgcg aaatggttat 540ggctctactc aatacattag atttagccca gattttacat ttggttttga ggagtcactt 600gaagttgata caaatcctct tttaggtgca ggcaaatttg ctacagatcc agcagtaaca 660ttagcacatg aacttataca tgctggacat agattatatg gaatagcaat taatccaaat 720agggttttta aagtaaatac taatgcctat tatgaaatga gtgggttaga agtaagcttt 780gaggaactta gaacatttgg gggacatgat gcaaagttta tagatagttt acaggaaaac 840gaatttcgtc tatattatta taataagttt aaagatatag caagtacact taataaagct 900aaatcaatag taggtactac tgcttcatta cagtatatga aaaatgtttt taaagagaaa 960tatctcctat ctgaagatac atctggaaaa ttttcggtag ataaattaaa atttgataag 1020ttatagaaaa tgttaacaga gatttagaca gaggataatt ttgttaagtt ttttaaagta 1080cttaacagaa aaacatattt gaattttgat aaagccgtat ttaagataaa tatagtacct 1140aaggtaaatt acacaatata tgatggattt aatttaagaa atacaaattt agcagcaaac 1200tttaatggtc aaaatacaga aattaataat atgaatttta ctaaactaaa aaattttact 1260ggattgtttg aattttataa gttgctatgt gtaagaggga taataacttc taaaactaaa 1320tcattagata aaggatacaa taaggcatta aatgatttat gtatcaaagt taataattgg 1380gacttgtttt ttagtccttc agaagataat tttactaatg atctaaataa aggagaagaa 1440attacatctg atactaatat agaagcagca gaagaaaata ttagtttaga tttaatacaa 1500caatattatt taacctttaa ttttgataat gaacctgaaa atatttcaat agaaaatctt 1560tcaagtgaca ttataggcca attagaactt atgcctaata tagaaagatt tcctaatgga 1620aaaaagtatg agttagataa atatactatg ttccattatc ttcgtgctca agaatttgaa 1680catggtaaat ctaggattgc tttaacaaat tctgttaacg aagcattatt aaatcctagt 1740cgtgtttata catttttttc ttcagactat gtaaagaaag ttaataaagc tacggaggca 1800gctatgtttt taggctgggt agaacaatta gtatatgatt ttaccgatga aactagcgaa 1860gtaagtacta cggataaaat tgcggatata actataatta ttccatatat aggacctgct 1920ttaaatatag gtaatatgtt atataaagat gattttgtag gtgctttaat attttcagga 1980gctgttattc tgttagaatt tataccagag attgcaatac ctgtattagg tacttttgca 2040cttgtatcat atattgcgaa taaggttcta accgttcaaa caatagataa tgctttaagt 2100aaaagaaatg aaaaatggga tgaggtctat aaatatatag taacaaattg gttagcaaag 2160gttaatacac agattgatct aataagaaaa aaaatgaaag aagctttaga aaatcaagca 2220gaagcaacaa aggctataat aaactatcag tataatcaat atactgagga agagaaaaat 2280aatattaatt ttaatattga tgatttaagt tcgaaactta atgagtctat aaataaagct 2340atgattaata taaataaatt tttgaatcaa tgctctgttt catatttaat gaattctatg 2400atcccttatg gtgttaaacg gttagaagat tttgatgcta gtcttaaaga tgcattatta 2460aagtatatat atgataatag aggaacttta attggtcaag tagatagatt aaaagataaa 2520gttaataata cacttagtac agatatacct tttcagcttt ccaaataggt agataatcaa 2580agattattat ctacatttac tgaatatatt aagaatatta ttaatacttc tatattgaat 2640ttaagatatg aaagtaatca tttaatagac ttatctaggt atgcatcaaa aataaatatt 2700ggtagtaaag taaattttga tccaatagat aaaaatcaaa ttcaattatt taatttagaa 2760agtagtaaaa ttgaggtaat tttaaaaaat gctattgtat ataatagtat gtatgaaaat 2820tttagtacta gcttttggat aagaattcct aagtatttta acagtataag tctaaataat 2880gaatatacaa taataaattg tatggaaaat aattcaggat ggaaagtatc acttaattat 2940ggtgaaataa tctggacttt acaggatact caggaaataa aacaaagagt agtttttaaa 3000tagagtcaaa tgattaatat atcagattat ataaacagat ggatttttgt aactatcact 3060aataatagat taaataactc taaaatttat ataaatggaa gattaataga tgaaaaacca 3120atttcaaatt taggtaatat tcatgctagt aataatataa tgtttaaatt agatggttgt 3180agagatacac atagatatat ttggataaaa tattttaatc tttttgataa ggaattaaat 3240gaaaaagaaa tcaaagattt atatgataat caatcaaatt caggtatttt aaaagacttt 3300tggggtgatt atttacaata tgataaacca tagtatatgt taaatttata tgatccaaat 3360aaatatgtcg atgtaaataa tgtaggtatt agaggttata tgtatcttaa agggcctaga 3420ggtagcgtaa tgactacaaa catttattta aattcaagtt tgtatagggg gacaaaattt 3480attataaaaa aatatgcttc tggaaataaa gataatattg ttagaaataa tgatcgtgta 3540tatattaatg tagtagttaa aaataaagaa tataggttag ctactaatgc atcacaggca 3600ggcgtagaaa aaatactaag tgcattagaa atacctgatg taggaaatct aagtcaagta 3660gtagtaatga agtcaaaaaa tgatcaagga ataacaaata aatgcaaaat gaatttacaa 3720gataataatg ggaatgatat aggctttata ggatttcatc agtttaataa tatagctaaa 3780ctagtagcaa gtaattggta taatagacaa atagaaagat ctagtaggac tttgggttgc 3840tcatgggaat ttattcctgt agatgatgga tggggagaaa ggccactgta a 389123876DNAbotulinum toxin 2atgccagtta caataaataa ttttaattat aatgatccta ttgataatga caatattatt 60atgatggaac ctccatttgc aaggggtacg gggagatatt ataaagcttt taaaatcaca 120gatcgtattt ggataatacc cgaaagatat acttttggat ataaacctga ggattttaat 180aaaagttccg gtatttttaa tagagatgtt tgtgaatatt atgatccaga ttacttaaat 240accaatgata aaaagaatat atttttccaa acattgatca agttatttaa tagaatcaaa 300tcaaaaccat tgggtgaaaa gttattagag atgattataa atggtatacc ttatcttgga 360gatagacgtg ttccactcga agagtttaac acaaacattg ctagtgtaac tgttaataaa 420ttaattagta atccaggaga agtggagcga aaaaaaggta ttttcgcaaa tttaataata 480tttggacctg ggccagtttt aaatgaaaat gagactatag atataggtat acaaaatcat 540tttgcatcaa gggaaggctt tgggggtata atgcaaatga aattttgtcc agaatatgta 600agcgtattta ataatgttca agaaaacaaa ggcgcaagta tatttaatag acgtggatat 660ttttcagatc cagccttgat attaatgcat gaacttatac atgttttgca tggattatat 720ggcattaaag tagatgattt accaattgta ccaaatgaaa aaaaattttt tatgcaatct 780acagatacta tacaggcaga agaactatat acatttggag gacaagatcc cagcatcata 840tctccttcta cagataaaag tatctatgat aaagttttgc aaaattttag ggggatagtt 900gatagactta acaaggtttt agtttgcata tcagatccta acattaacat taatatatat 960aaaaataaat ttaaagataa atataaattc gttgaagatt ctgaaggaaa atatagtata 1020gatgtagaaa gtttcaataa attatataaa agcttaatgt taggttttac agaaattaat 1080atagcagaaa attataaaat aaaaactaga gcttcttatt ttagtgattc cttaccacca 1140gtaaaaataa aaaatttatt agataatgaa atctatacta tagaggaagg gtttaatata 1200tctgataaaa atatgggaaa agaatatagg ggtcagaata aagctataaa taaacaagct 1260tatgaagaaa tcagcaagga gcatttggct gtatataaga tacaaatgtg taaaagtgtt 1320aaagttccag gaatatgtat tgatgtcgat aatgaaaatt tgttctttat agctgataaa 1380aatagttttt cagatgattt atctaaaaat gaaagagtag aatataatac acagaataat 1440tatataggaa atgactttcc tataaatgaa ttaattttag atactgattt aataagtaaa 1500atagaattac caagtgaaaa tacagaatca cttactgatt ttaatgtaga tgttccagta 1560tatgaaaaac aacccgctat aaaaaaagtt tttacagatg aaaataccat ctttcaatat 1620ttatactctc agacatttcc tctaaatata agagatataa gtttaacatc ttcatttgat 1680gatgcattat tagtttctag caaagtttat tcattttttt ctatggatta tattaaaact 1740gctaataaag tagtagaagc aggattattt gcaggttggg tgaaacagat agtagatgat 1800tttgtaatcg aagctaataa aagcagtact atggataaaa ttgcagatat atctctaatt 1860gttccttata taggattagc tttaaatgta ggagatgaaa cagctaaagg aaattttgaa 1920agtgcttttg agattgcagg atccagtatt ttactagaat ttataccaga acttttaata 1980cctgtagttg gagtcttttt attagaatca tatattgaca ataaaaataa aattattaaa 2040acaatagata atgctttaac taaaagagtg gaaaaatgga ttgatatgta gggattaata 2100gtagcgcaat ggctctcaac agttaatact caattttata caataaaaga gggaatgtat 2160aaggctttaa attatcaagc acaagcattg gaagaaataa taaaatacaa atataatata 2220tattctgaag aggaaaagtc aaatattaac atcaatttta atgatataaa ttctaaactt 2280aatgatggta ttaaccaagc tatggataat ataaatgatt ttataaatga atgttctgta 2340tcatatttaa tgaaaaaaat gattccatta gctgtaaaaa aattactaga ctttgataat 2400actctcaaaa aaaatttatt aaattatata gatgaaaata aattatattt aattggaagt 2460gtagaagatg aaaaatcaaa agtagataaa tacttgaaaa ccattatacc atttgatctt 2520tcaacgtatt ctaatattga aatactaata aaaatattta ataaatataa tagcgaaatt 2580ttaaataata ttatcttaaa tttaagatat agagataata atttaataga tttatcagga 2640tatggagcaa aggtagaggt atatgatggg gtcaagctta atgataaaaa tcaatttaaa 2700ttaactagtt cagcagatag taagattaga gtcactcaaa atcagaatat tatatttaat 2760agtatgttcc ttgattttag cgttagcttt tggataagga tacctaaata taggaatgat 2820gatatacaaa attatattca taatgaatat acgataatta attgtatgaa aaataattca 2880ggctggaaaa tatctattag gggtaatagg ataatatgga ccttaattga tataaatgga 2940aaaaccaaat cagtattttt tgaatataac ataagagaag atatatcaga gtatataaat 3000agatggtttt ttgtaactat tactaataat ttggataatg ctaaaattta tattaatggc 3060acgttagaat caaatatgga tattaaagat ataggagaag ttattgttaa tggtgaaata 3120acatttaaat tagatggtga tgtagataga acacaattta tttggatgaa atattttagt 3180atttttaata cgcaattaaa tcaatcaaat attaaagaga tatataaaat tcaatcatat 3240agcgaatagt taaaagattt ttggggaaat cctttaatgt ataataaaga atattatatg 3300tttaatgcgg ggaataaaaa ttcatatatt aaactagtga aagattcatc tgtaggtgaa 3360atattaatac gtagcaaata taatcagaat tccaattata taaattatag aaatttatat 3420attggagaaa aatttattat aagaagagag tcaaattctc aatctataaa tgatgatata 3480gttagaaaag aagattatat acatctagat ttggtacttc accatgaaga gtggagagta 3540tatgcctata aatattttaa ggaacaggaa gaaaaattgt ttttatctat tataagtgat 3600tctaatgaat tttataagac tatagaaata aaagaatatg atgaacagcc atcatatagt 3660tgtcagttgc tttttaaaaa agatgaagaa agtactgatg atataggatt gattggtatt 3720catcgtttct aggaatctgg agttttacgt aaaaagtata aagattattt ttgtataagt 3780aaatggtagt taaaagaggt aaaaaggaaa ccatataagt caaatttggg atgtaattgg 3840cagtttattc ctaaagatga agggtggact gaataa 387633876DNAbotulinum toxin 3atgccagtta caataaataa ttttaattat aatgatccta ttgataataa taatattatt 60atgatggagc ctccatttgc gagaggtacg gggagatatt ataaagcttt taaaatcaca 120gatcgtattt ggataatacc ggaaagatat acttttggat ataaacctga ggattttaat 180aaaagttccg gtatttttaa tagagatgtt tgtgaatatt atgatccaga ttagttaaat 240actaatgata aaaagaatat atttttacaa acaatgatca agttatttaa tagaatcaaa 300tcaaaaccat tgggtgaaaa gttattagag atgattataa atggtatacc ttatcttgga 360gatagacgtg ttccactcga agagtttaac acaaacattg ctagtgtaac tgttaataaa 420ttaatcagta atccaggaga agtggagcga aaaaaaggta ttttcgcaaa tttaataata 480tttggacctg ggccagtttt aaatgaaaat gagactatag atataggtat acaaaatcat 540tttgcatcaa gggaaggctt cgggggtata atgcaaatga agttttgccc agaatatgta 600agcgtattta ataatgttca agaaaacaaa ggcgcaagta tatttaatag acgtggatat 660ttttcagatc cagccttgat attaatgcat gaacttatac atgttttaca tggattatat 720ggcattaaag tagatgattt accaattgta ccaaatgaaa aaaaattttt tatgcaatct 780acagatgcta tacaggcaga agaactatat acatttggag gacaagatcc cagcatcata 840actccttcta cggataaaag tatctatgat aaagttttgc aaaattttag agggatagtt 900gatagactta acaaggtttt agtttgcata tcagatccta acattaatat taatatatat 960aaaaataaat ttaaagataa atataaattc gttgaagatt ctgagggaaa atatagtata 1020gatgtagaaa gttttgataa attatataaa agcttaatgt ttggttttac agaaactaat 1080atagcagaaa attataaaat aaaaactaga gcttcttatt ttagtgattc cttaccacca 1140gtaaaaataa aaaatttatt agataatgaa atctatacta tagaggaagg gtttaatata 1200tctgataaag atatggaaaa agaatataga ggtcagaata aagctataaa taaacaagct 1260tatgaagaaa ttagcaagga gcatttggct gtatataaga tacaaatgtg taaaagtgtt 1320aaagctccag gaatatgtat tgatgttgat aatgaagatt tgttctttat agctgataaa 1380aatagttttt cagatgattt atctaaaaac gaaagaatag aatataatac acagagtaat 1440tatatagaaa atgacttccc tataaatgaa ttaattttag atactgattt aataagtaaa 1500atagaattac caagtgaaaa tacagaatca cttactgatt ttaatgtaga tgttccagta 1560tatgaaaaac aacccgctat aaaaaaaatt tttacagatg aaaataccat ctttcaatat 1620ttatagtctc agacatttct cttagatata agagatataa gtttaacatc ttcatttgat 1680gatgcattat tattttctaa caaagtttat tcattttttt ctatggatta tattaaaact 1740gctaataaag tggtagaagc aggattattt gcaggttggg tgaaacagat agtaaatgat 1800tttgtaatcg aagctaataa aagcaatact atggataaaa ttgcagatat atctctaatt 1860gttccttata taggattagc tttaaatgta ggaaatgaaa cagctaaagg aaattttgaa 1920aatgcttttg agattgcagg agccagtatt ctactagaat ttataccaga acttttaata 1980cctgtagttg gagccttttt attagaatca tatattgaca ataaaaataa aattattaaa 2040acaatagata atgctttaac taaaagaaat gaaaaatgga gtgatatgta gggattaata 2100gtagcgcaat ggctctcaac agttaatact caattttata caataaaaga gggaatgtat 2160aaggctttaa attatcaagc acaagcattg gaagaaataa taaaatacag atataatata 2220tattctgaaa aagaaaagtc aaatattaac atcgatttta atgatataaa ttctaaactt 2280aatgagggta ttaaccaagc tatagataat ataaataatt ttataaatgg atgttctgta 2340tcatatttaa tgaaaaaaat gattccatta gctgtagaaa aattactaga ctttgataat 2400actctcaaaa aaaatttgtt aaattatata gatgaaaata aattatattt gattggaagt 2460gcagaatatg aaaaatcaaa agtaaataaa tagttgaaaa ccattatgcc gtttgatctt 2520tcaatatata ccaatgatac aatactaata gaaatgttta ataaatataa tagcgaaatt 2580ttaaataata ttatcttaaa tttaagatat aaggataata atttaataga tttatcagga 2640tatggggcaa aggtagaggt atatgatgga gtcgagctta atgataaaaa tcaatttaaa 2700ttaactagtt cagcaaatag taagattaga gtgactcaaa atcagaatat catatttaat 2760agtgtgttcc ttgattttag cgttagcttt tggataagaa tacctaaata taagaatgat 2820ggtatacaaa attatattca taatgaatat acaataatta attgtatgaa aaataattcg 2880ggctggaaaa tatctattag gggtaatagg ataatatgga ctttaattga tataaatgga 2940aaaaccaaat cggtattttt tgaatataac ataagagaag atatatcaga gtatataaat 3000agatggtttt ttgtaactat tactaataat ttgaataacg ctaaaattta tattaatggt 3060aagctagaat caaatacaga tattaaagat ataagagaag ttattgctaa tggtgaaata 3120atatttaaat tagatggtga tatagataga acacaattta tttggatgaa atatttcagt 3180atttttaata cggaattaag tcaatcaaat attgaagaaa gatataaaat tcaatcatat 3240agcgaatatt taaaagattt ttggggaaat cctttaatgt agaataaaga atattatatg 3300tttaatgcgg ggaataaaaa ttcatatatt aaactaaaga aagattcacc tgtaggtgaa 3360attttaacac gtagcaaata taatcaaaat tctaaatata taaattatag agatttatat 3420attggagaaa aatttattat aagaagaaag tcaaattctc aatctataaa tgatgatata 3480gttagaaaag aagattatat atatctagat ttttttaatt taaatcaaga gtggagagta 3540tatacctata aatattttaa gaaagaggaa gaaaaattgt ttttagctcc tataagtgat 3600tctgatgagt tttagaatac tatacaaata aaagaatatg atgaacagcc aacatatast 3660tgtcagttgc tttttaaaaa agatgaagaa agtactgatg agataggatt gattggtatt 3720catcgtttct aggaatctgg aattgtattt gaagagtata aagattattt ttgtataagt 3780aaatggtagt taaaagaggt aaaaaggaaa ccatataatt taaaattggg atgtaattgg 3840cagtttattc ctaaagatga agggtggact gaataa 387643876DNAbotulinum toxin 4atgccaataa caattaacaa ctttaattat tcagatcctg ttgataataa aaatatttta 60tatttagata ctcatttaaa tacactagct aatgagcctg aaaaagcctt tcgcattaca 120ggaaatatat gggtaatacc tgatagattt tcaagaaatt ctaatccaaa tttaaataaa 180cctcctcgag ttacaagccc taaaagtggt tattatgatc ctaattattt gagtactgat 240tctgacaaag atacattttt aaaagaaatt ataaagttat ttaaaagaat taattctaga 300gaaataggag aagaattaat atatagactt tcgacagata taccctttcc tgggaataac 360aatactccaa ttaatacttt tgattttgat gtagatttta acagtgttga tgttaaaact 420agacaaggta acaactgggt taaaactggt agcataaatc ctagtgttat aataactgga 480cctagagaaa acattataga tccagaaact tctacgttta aattaactaa caatactttt 540gcggcacaag aaggatttgg tgctttatca ataatttcaa tatcacctag atttatgcta 600acatatagta atgcaactaa tgatgtagga gagggtagat tttctaagtc tgaattttgc 660atggatccaa tactaatttt aatgcatgaa cttaatcatg caatgcataa tttatatgga 720atagctatac caaatgatca aacaatttca tctgtaacta gtaatatttt ttattctcaa 780tataatgtga aattagagta tgcagaaata tatgcatttg gaggtccaac tatagacctt 840attcctaaaa gtgcaaggaa atattttgag gaaaaggcat tggattatta tagatctata 900gctaaaagac ttaatagtat aactactgca aatccttcaa gctttaataa atatataggg 960gaatataaac agaaacttat tagaaagtat agattcgtag tagaatcttc aggtgaagtt 1020acagtaaatc gtaataagtt tgttgagtta tataatgaac ttacacaaat atttacagaa 1080tttaactagg ctaaaatata taatgtacaa aataggaaaa tatatctttc aaatgtatat 1140actccggtta cggcgaatat attagacgat aatgtttatg atatacaaaa tggatttaat 1200atacctaaaa gtaatttaaa tgtactattt atgggtcaaa atttatctcg aaatccagca 1260ttaagaaaag tcaatcctga aaatatgctt tatttattta caaaattttg tcataaagca 1320atagatggta gatcattata taataaaaca ttagattgta gagagctttt agttaaaaat 1380actgacttac cctttatagg tgatattagt gatgttaaaa ctgatatatt tttaagaaaa 1440gatattaatg aagaaactga agttatatac tatccggaca atgtttcagt agatcaagtt 1500attctcagta agaatacctc agaacatgga caactagatt tattataccc tagtattgac 1560agtgagagtg aaatattacc aggggagaat caagtctttt atgataatag aactcaaaat 1620gttgattatt tgaattctta ttattaccta gaatctcaaa aactaagtga taatgttgaa 1680gattttactt ttacgagatc aattgaggag gctttggata atagtgcaaa agtatatact 1740tactttccta cactagctaa taaagtaaat gcgggtgttc aaggtggttt atttttaatg 1800tgggcaaatg atgtagttga agattttact acaaatattc taagaaaaga tacattagat 1860aaaatatcag atgtatcagc tattattccc tatataggac ccgcattaaa tataagtaat 1920tctgtaagaa gaggaaattt tactgaagca tttgcagtta ctggtgtaac tattttatta 1980gaagcatttc ctgaatttac aatacctgca cttggtgcat ttgtgattta tagtaaggtt 2040caagaaagaa acgagattat taaaactata gataattgtt tagaacaaag gattaagaga 2100tggaaagatt catatgaatg gatgatggga acgtggttat ccaggattat tactcaattt 2160aataatataa gttatcaaat gtatgattct ttaaattatc aggcaggtgc aatcaaagct 2220aaaatagatt tagaatataa aaaatattca ggaagtgata aagaaaatat aaaaagtcaa 2280gttgaaaatt taaaaaatag tttagatgta aaaatttcgg aagcaatgaa taatataaat 2340aaatttatac gagaatgttc cgtaacatat ttatttaaaa atatgttacc taaagtaatt 2400gatgaattaa atgagtttga tcgaaatact aaagcaaaat taattaatct tatagatagt 2460cataatatta ttctagttgg tgaagtagat aaattaaaag caaaagtaaa taatagcttt 2520caaaatacaa taccctttaa tattttttca tatactaata attctttatt aaaagatata 2580attaatgaat atttcaataa tattaatgat tcaaaaattt tgagcctaca aaacagaaaa 2640aatactttag tggatacatc aggatataat gcagaagtga gtgaagaagg cgatgttcag 2700cttaatccaa tatttccatt tgactttaaa ttaggtagtt caggggagga tagaggtaaa 2760gttatagtaa cccagaatga aaatattgta tataattcta tgtatgaaag ttttagcatt 2820agtttttgga ttagaataaa taaatgggta agtaatttac ctggatatac tataattgat 2880agtgttaaaa ataactcagg ttggagtata ggtattatta gtaatttttt agtatttact 2940ttaaaacaaa atgaagatag tgaacaaagt ataaatttta gttatgatat atcaaataat 3000gctcctggat agaataaatg gttttttgta actgttacta acaatatgat gggaaatatg 3060aagatttata taaatggaaa attaatagat actataaaag ttaaagaact aactggaatt 3120aattttagca aaactataac atttgaaata aataaaattc cagataccgg tttgattact 3180tcagattctg ataacatcaa tatgtggata agagattttt atatatttgc taaagaatta 3240gatggtaaag atattaatat

attatttaat agcttgcaat atactaatgt tgtaaaagat 3300tattggggaa atgatttaag atataataaa gaatattata tggttaatat agattattta 3360aatagatata tgtatgcgaa ctcacgacaa attgttttta atacacgtag aaataataat 3420gacttcaatg aaggatataa aattataata aaaagaatca gaggaaatac aaatgatact 3480agagtacgag gaggagatat tttatatttt gatatgacaa ttaataacaa agcatataat 3540ttgtttatga agaatgaaac tatgtatgca gataatcata gtactgaaga tatatatgct 3600ataggtttaa gagaacaaac aaaggatata aatgataata ttatatttca aatacaacca 3660atgaataata cttattatta ggcatctcaa atatttaaat caaattttaa tggagaaaat 3720atttctggaa tatgttcaat aggtacttat cgttttagac ttggaggtga ttggtataga 3780cacaattatt tggtgcctac tgtgaagcaa ggaaattatg cttcattatt agaatcaaca 3840tcaactcatt ggggttttgt acctgtaagt gaataa 387653831DNAbotulinum toxin 5atgacatggc cagtaaaaga ttttaattat agtgatcctg ttaatgacaa tgatatatta 60tatttaagaa taccacaaaa taagttaatt actacacctg taaaagcttt tatgattact 120caaaatattt gggtaatacc agaaagattt tcatcagata ctaatccaag tttaagtaaa 180ccgcccagac ctacttcaaa gtatcaaagt tattatgatc ctagttattt atctactgat 240gaacaaaaag atacattttt aaaagggatt ataaaattat ttaaaagaat taatgaaaga 300gatataggaa aaaaattaat aaattattta gtagttggtt caccttttat gggagattca 360agtacgcctg aagatacatt tgattttaca cgtcatacta ctaatattgc agttgaaaag 420tttgaaaatg gtagttggaa agtaacaaat attataacac caagtgtatt gatatttgga 480ccacttccta atatattaga ctatacagca tcccttacat tgcaaggaca acaatcaaat 540ccatcatttg aagggtttgg aacattatct atactaaaag tagcacctga atttttgtta 600acatttagtg atgtaacatc taatcaaagt tcagctgtat taggcaaatc tatattttgt 660atggatccag taatagcttt aatgcatgag ttaacacatt ctttgcatca attatatgga 720ataaatatac catctgataa aaggattcgt ccacaagtta gcgagggatt tttctctcaa 780gatggaccca acgtacaatt tgaggaatta tatacatttg gaggattaga tgttgaaata 840atacctcaaa ttgaaagatc acaattaaga gaaaaagcat taggtcacta taaagatata 900gcgaaaagac ttaataatat taataaaact attccttcta gttggattag taatatagat 960aaatataaaa aaatattttc tgaaaagtat aattttgata aagataatac aggaaatttt 1020gttgtaaata ttgataaatt caatagctta tattcagact tgactaatgt tatgtcagaa 1080gttgtttatt cttcgcaata taatgttaaa aacaggactc attatttttc aaggcattat 1140ctacctgtat ttgcaaatat attagatgat aatatttata ctataagaga tggttttaat 1200ttaacaaata aaggttttaa tatagaaaat tcgggtcaga atatagaaag gaatcctgca 1260ctacaaaagc ttagttcaga aagtgtagta gatttattta caaaagtatg tttaagatta 1320acaaaaaata gtagagatga ttcaacatgt attaaagtta aaaataatag attaccttat 1380gtagctgata aagatagcat ttcacaagaa atatttgaaa ataaaattat tacagatgag 1440actaatgtac aaaattattc agataatttt tcattagatg aatctatttt agatgggcaa 1500gttcctatta atcctgaaat agtagatcca ctattaccca atgttaatat ggaaccttta 1560aatcttccag gtgaagaaat agtattttat gatgatatta ctaaatatgt tgattattta 1620aattcttatt attatttgga atctcaaaaa ttaagtaata atgttgaaaa tattactctt 1680acaacttcag ttgaagaagc attaggttat agcaataaga tatagacatt tttacctagc 1740ttagctgaaa aagtgaataa aggtgttcaa gcaggtttat tcttaaattg ggcgaatgaa 1800gtagttgagg attttactac aaatattatg aagaaagata cattggataa aatatcagat 1860gtatcagtaa taattccata tataggacct gccttaaata taggaaattc agcattaagg 1920ggaaatttta agcaagcatt tgcaacagct ggtgtagctt ttttattaga gggatttcca 1980gagtttacta tacctgcact cggtgtattt accttttata gttctattca agaaagagag 2040aaaattatta aaactataga aaattgtttg gaacaaagag ttaagagatg gaaagattca 2100tatcaatgga tggtatcaaa ttggttgtca agaattacta ctcaatttaa tcatataaat 2160tatcaaatgt atgattcttt aagttatcag gcagatgcaa tcaaagctaa aatagattta 2220gaatataaaa aatagtcagg aagtgataaa gaaaatataa aaagtcaagt tgaaaattta 2280aaaaatagtt tagatgtaaa aatttcggaa gcaatgaata atataaataa atttatacga 2340gaatgttctg taacatagtt atttaaaaat atgctcccta aagtaattga cgaattaaat 2400aagtttgatt taagaactaa aacagaatta attaatctta tagatagtca taatattatt 2460ctagttggtg aagtagatag attaaaagca aaagtaaatg agagttttga aaatacaatg 2520ccttttaata ttttttcata tactaataat tctttattaa aagatataat taatgaatat 2580ttcaatagta ttaatgattc aaaaattttg agcttacaaa acaaaaaaaa tgctttagtg 2640gatacatcag gatataatgc agaagtgagg gtaggagata atgttcaact taatacgata 2700tatacaaatg actttaaatt aagtagttca ggagataaaa ttatagtaaa tttaaataat 2760aatattttat atagcgctat ttatgagaac tctagtgtta gtttttggat taagatatct 2820aaagatttaa ctaattctca taatgaatat acaataatta acagtataga acaaaattct 2880gggtggaaat tatgtattag gaatggcaat atagaatgga ttttacaaga tgttaataga 2940aagtataaaa gtttaatttt tgattatagt gaatcattaa gtcatacagg atatacaaat 3000aaatggtttt ttgttactat aactaataat ataatggggt atatgaaact ttatataaat 3060ggagaattaa agcagagtca aaaaattgaa gatttagatg aggttaagtt agataaaacc 3120atagtatttg gaatagatga gaatatagat gagaatcaga tgctttggat tagagatttt 3180aatatttttt ctaaagaatt aagtaatgaa gatattaata ttgtatatga gggacaaata 3240ttaagaaatg ttattaaaga ttattgggga aatcctttga agtttgatac agaatattat 3300attattaatg ataattatat agataggtat attgcacctg aaagtaatgt acttgtactt 3360gttcggtatc cagatagatc taaattatat actggaaatc ctattactat taaatcagta 3420tctgataaga atccttatag tagaatttta aatggagata atataattct tcatatgtta 3480tataatagta ggaaatatat gataataaga gatactgata caatatatgc aacacaagga 3540ggagagtgtt cacaaaattg tgtatatgca ttaaaattac agagtaattt aggtaattat 3600ggtataggta tatttagtat aaaaaatatt gtatctaaaa ataaatattg tagtcaaatt 3660ttctctagtt ttagggaaaa tacaatgctt ctagcagata tatataaacc ttggagattt 3720tcttttaaaa atgcatagac gccagttgca gtaactaatt atgaaacaaa actattatca 3780acttcatctt tttggaaatt tatttctagg gatccaggat gggtagagta a 383163753DNAbotulinum toxin 6atgccaacaa ttaatagttt taattataat gatcctgtta ataatagaac aattttatat 60attaaaccag gcggttgtca acaattttat aaatcattta atattatgaa aaatatttgg 120ataattccag agagaaatgt aattggtaca attccccaag attttcttcc gcctacttca 180ttgaaaaatg gagatagtag ttattatgac cctaattatt tacaaagtga tcaagaaaag 240gataaatttt taaaaatagt cacaaaaata tttaatagaa taaatgataa tctttcagga 300aggattttat tagaagaact gtcaaaagct aatccatatt taggaaatga taatactcca 360gatggtgact tcattattaa tgatgcatca gcagttccaa ttcaattctc aaatggtagc 420caaagcatac tattacctaa tgttattata atgggagcag agcctgattt atttgaaact 480aacagttcca atatttctct aagaaataat tatatgccaa gcaatcacgg ttttggatca 540atagctatag taacattctc acctgaatat tcttttagat ttaaagataa tagtatgaat 600gaatttattc aagatcctgc tcttacatta atgcatgaat taatacattc attacatgga 660ctatatgggg ctaaagggat tactacaaag tatactataa cacaaaaaca aaatccccta 720ataacaaata taagaggtac aaatattgaa gaattcttaa cttttggagg tactgattta 780aacattatta ctagtgctca gtccaatgat atctatacta atcttctagc tgattataaa 840aaaatagcgt ctaaacttag caaagtacaa gtatctaatc cactacttaa tccttataaa 900gatgtttttg aagcaaagta tggattagat aaagatgcta gcggaattta ttcggtaaat 960ataaacaaat ttaatgatat ttttaaaaaa ttatacagct ttacggaatt tgatttagca 1020actaaatttc aagttaaatg taggcaaact tatattggac agtataaata cttcaaactt 1080tcaaacttgt taaatgattc tatttataat atatcagaag gctataatat aaataattta 1140aaggtaaatt ttagaggaca gaatgcaaat ttaaatccta gaattattac accaattaca 1200ggtagaggac tagtaaaaaa aatcattaga ttttgtaaaa atattgtttc tgtaaaaggc 1260ataaggaaat caatatgtat cgaaataaat aatggtgagt tattttttgt ggcttccgag 1320aatagttata atgatgataa tataaatact cctaaagaaa ttgacgatac agtaacttca 1380aataataatt atgaaaatga tttagatcag gttattttaa attttaatag tgaatcagca 1440cctggacttt cagatgaaaa attaaattta actatccaaa atgatgctta tataccaaaa 1500tatgattcta atggaacaag tgatatagaa caacatgatg ttaatgaact taatgtattt 1560ttctatttag atgcacagaa agtgcccgaa ggtgaaaata atgtcaatct cacctcttca 1620attgatacag cattattaga acaacctaaa atatatacat ttttttcatc agaatttatt 1680aataatgtca ataaacctgt gcaagcagca ttatttgtaa gctggataca acaagtatta 1740gtagatttta ctactgaagc taaccaaaaa agtactgttg ataaaattgc agatatttct 1800atagttgttc catatatagg tcttgcttta aatataggaa atgaagcaca aaaaggaaat 1860tttaaagatg cacttgaatt attaggagca ggtattttat tagaatttga acccgagctt 1920ttaattccta caattttagt attcacgata aaatcttttt taggttcatc tgataataaa 1980aataaagtta ttaaagcaat aaataatgca ttgaaagaaa gagatgaaaa atggaaagaa 2040gtatatagtt ttatagtatc gaattggatg actaaaatta atacacaatt taataaaaga 2100aaagaacaaa tgtatcaagc tttacaaaat caagtaaatg cacttaaagc aataatagaa 2160tctaagtata atagttatac tttagaagaa aaaaatgagc ttacaaataa atatgatatt 2220gagcaaatag aaaatgaact taatcaaaag gtttctatag caatgaataa tatagacagg 2280ttcttaactg aaagttctat atcttattta atgaaattaa taaatgaagt aaaaattaat 2340aaattaagag aatatgatga aaatgttaaa acgtatttat tagattatat tataaaacat 2400ggatcaatct tgggagagag tcagcaagaa ctaaattcta tggtaattga taccctaaat 2460aatagtattc cttttaagct ttcttcttat acagatgata aaattttaat ttcatatttt 2520aataagttct ttaagagaat taaaagtagt tctgttttaa atatgagata taaaaatgat 2580aaataggtag atacttcagg atatgattca aatataaata ttaatggaga tgtatataaa 2640tatccaacta ataaaaatca atttggaata tataatgata aacttagtga agttaatata 2700tctcaaaatg attacattat atatgataat aaatataaaa attttagtat tagtttttgg 2760gtaagaattc ctaactatga taataagata gtaaatgtta ataatgaata cactataata 2820aattgtatga gggataataa ttcaggatgg aaagtatctc ttaatcataa tgaaataatt 2880tggacattgc aagataattc aggaattaat caaaaattag catttaacta tggtaacgca 2940aatggtattt ctgattatat aaataagtgg atttttgtaa ctataactaa tgatagatta 3000ggagattcta aactttatat taatggaaat ttaatagata aaaaatcaat tttaaattta 3060ggtaatattc atgttagtga caatatatta tttaaaatag ttaattgtag ttatacaaga 3120tatattggta ttagatattt taatattttt gataaagaat tagatgaaac agaaattcaa 3180actttatata acaatgaacc taatgcaaat attttaaagg atttttgggg aaattatttg 3240ctttatgaca aagaatagta tttattaaat gtgttaaaac caaataactt tattaatagg 3300agaacagatt ctactttaag cattaataat ataagaagca ctattctttt agctaataga 3360ttatatagtg gaataaaagt taaaatacaa agagttaata atagtagtac taacgataat 3420cttgttagaa agaatgatca ggtatatatt aattttgtag ccagcaaaac tcacttactt 3480ccattatatg ctgatacagc taccacaaat aaagagaaaa caataaaaat atcatcatct 3540ggcaatagat ttaatcaagt agtagttatg aattcagtag gatgtacaat gaattttaaa 3600aataataatg gaaataatat tgggttgtta ggtttcaagg cagatactgt agttgctagt 3660acttggtatt atacacatat gagagataat acaaacagca atggattttt ttggaacttt 3720atttctgaag aacatggatg gcaagaaaaa taa 375373759DNAbotulinum toxin 7atgccaaaaa ttaatagttt taattataat gatcctgtta atgatagaac aattttatat 60attaaaccag gcggttgtca agaattttat aaatcattta atattatgaa aaatatttgg 120ataattccag agagaaatgt aattggtaca accccccaag attttcatcc gcctacttca 180ttaaaaaatg gagatagtag ttattatgac cctaattatt tacaaagtga tgaagaaaag 240gatagatttt taaaaatagt cacaaaaata tttaatagaa taaataataa tctttcagga 300gggattttat tagaagaact gtcaaaagct aatccatatt tagggaatga taatactcca 360gataatcaat tccatattgg tgatgcatca gcagttgaga ttaaattctc aaatggtagc 420caagacatac tattacctaa tgttattata atgggagcag agcctgattt atttgaaact 480aacagttcca atatttctct aagaaataat tatatgccaa gcaatcacgg ttttggatca 540atagctatag taacattctc acctgaatat tcttttagat ttaatgataa tagtatgaat 600gaatttattc aagatcctgc tcttacatta atgcatgaat taatacattc attacatgga 660ctatatgggg ctaaagggat tactacaaag tatactataa cacaaaaaca aaatccccta 720ataacaaata taagaggtac aaatattgaa gaattcttaa cttttggagg tactgattta 780aacattatta ctagtgctca gtccaatgat atctatacta atcttctagc tgattataaa 840aaaatagcgt ctaaacttag caaagtacaa gtatctaatc cactacttaa tccttataaa 900gatgtttttg aagcaaagta tggattagat aaagatgcta gcggaattta ttcggtaaat 960ataaacaaat ttaatgatat ttttaaaaaa ttatagagct ttacggaatt tgatttagca 1020actaaatttc aagttaaatg taggcaaact tatattggac agtataaata cttcaaactt 1080tcaaacttgt taaatgattc tatttataat atatcagaag gctataatat aaataattta 1140aaggtaaatt ttagaggaca gaatgcaaat ttaaatccta gaattattac accaattaca 1200ggtagaggac tagtaaaaaa aatcattaga ttttgtaaaa atattgtttc tgtaaaaggc 1260ataaggaaat caatatgtat cgaaataaat aatggtgagt tattttttgt ggcttccgag 1320aatagttata atgatgataa tataaatact cctaaagaaa ttgacgatac agtaacttca 1380aataataatt atgaaaatga tttagatcag gttattttaa attttaatag tgaatcagca 1440cctggacttt cagatgaaaa attaaattta actatccaaa atgatgctta tataccaaaa 1500tatgattcta atggaacaag tgatatagaa caacatgatg ttaatgaact taatgtattt 1560ttctatttag atgcacagaa agtgcccgaa ggtgaaaata atgtcaatct cacctcttca 1620attgatacag cattattaga acaacctaaa atatatacat ttttttcatc agaatttatt 1680aataatgtca ataaacctgt gcaagcagca ttatttgtaa gctggataca acaagtgtta 1740gtagatttta ctactgaagc taaccaaaaa agtactgttg ataaaattgc agatatttct 1800atagttgttc catatatagg tcttgcttta aatataggaa atgaagcaca aaaaggaaat 1860tttaaagatg cacttgaatt attaggagca ggtattttat tagaatttga acccgagctt 1920ttaattccta caattttagt attcacgata aaatcttttt taggttcatc tgataataaa 1980aataaagtta ttaaagcaat aaataatgca ttgaaagaaa gagatgaaaa atggaaagaa 2040gtatatagtt ttatagtatc gaattggatg actaaaatta atacacaatt taataaaaga 2100aaagaacaaa tgtatcaagc tttacaaaat caagtaaatg caattaaaac aataatagaa 2160tctaagtata atagttatac tttagaggaa aaaaatgagc ttacaaataa atatgatatt 2220aagcaaatag aaaatgaact taatcaaaag gtttctatag caatgaataa tatagacagg 2280ttcttaactg aaagttctat atcctattta atgaaattaa taaatgaagt aaaaattaat 2340aaattaagag aatatgatga gaatgtcaaa acgtatttat tgaattatat tatacaacat 2400ggatcaatct tgggagagag tcagcaagaa ctaaattcta tggtaactga taccctaaat 2460aatagtattc cttttaagct ttcttcttat acagatgata aaattttaat ttcatatttt 2520aataaattct ttaagagaat taaaagtagt tcagttttaa atatgagata taaaaatgat 2580aaatacgtag atacttcagg atatgattca aatataaata ttaatggaga tgtatataaa 2640tatccaacta ataaaaatca atttggaata tataatgata aacttagtga agttaatata 2700tctcaaaatg attagattat atatgataat aaatataaaa attttagtat tagtttttgg 2760gtaagaattc ctaactatga taataagata gtaaatgtta ataatgaata gactataata 2820aattgtatga gagataataa ttcaggatgg aaagtatctc ttaatcataa tgaaataatt 2880tggacattgc aagataatgc aggaattaat caaaaattag catttaacta tggtaacgca 2940aatggtattt ctgattatat aaataagtgg atttttgtaa ctataactaa tgatagatta 3000ggagattcta aactttatat taatggaaat ttaatagatc aaaaatcaat tttaaattta 3060ggtaatattc atgttagtga caatatatta tttaaaatag ttaattgtag ttatacaaga 3120tatattggta ttagatattt taatattttt gataaagaat tagatgaaac agaaattcaa 3180actttatata gcaatgaacc taatacaaat attttgaagg atttttgggg aaattatttg 3240ctttatgaca aagaatacta tttattaaat gtgttaaaac caaataactt tattgatagg 3300agaaaagatt ctactttaag cattaataat ataagaagca ctattctttt agctaataga 3360ttatatagtg gaataaaagt taaaatacaa agagttaata atagtagtac taacgataat 3420cttgttagaa agaatgatca ggtatatatt aattttgtag ccagcaaaac tcacttattt 3480ccattatatg ctgatacagc taccacaaat aaagagaaaa caataaaaat atcatcatct 3540ggcaatagat ttaatcaagt agtagttatg aattcagtag gaaataattg tacaatgaat 3600tttaaaaata ataatggaaa taatattggg ttgttaggtt tcaaggcaga tactgtagtt 3660gctagtactt ggtattatac acatatgaga gatcatacaa acagcaatgg atgtttttgg 3720aactttattt ctgaagaaca tggatggcaa gaaaaataa 375983825DNAbotulinum toxin 8atgccagttg caataaatag ttttaattat aatgaccctg ttaatgatga tacaatttta 60tagatgcaga taccatatga agaaaaaagt aaaaaatatt ataaagcttt tgagattatg 120cgtaatgttt ggataattcc tgagagaaat acaataggaa cgaatcctag tgattttgat 180ccaccggctt cattaaagaa cggaagcagt gcttattatg atcctaatta tttaaccact 240gatgctgaaa aagatagata tttaaaaaca acgataaaat tatttaagag aattaatagt 300aatcctgcag ggaaagtttt gttacaagaa atatcatatg ctaaaccata tttaggaaat 360gaccacacgc caattgatga attctctcca gttactagaa ctacaagtgt taatataaaa 420ttatcaacta atgttgaaag ttcaatgtta ttgaatcttc ttgtattggg agcaggacct 480gatatatttg aaagttgttg ttaccccgtt agaaaactaa tagatccaga tgtagtttat 540gatccaagta attatggttt tggatcaatt aatatcgtga cattttcacc tgagtatgaa 600tatactttta atgatattag tggagggcat aatagtagta cagaatcatt tattgcagat 660cctgcaattt cactagctca tgaattgata catgcactgc atggattata cggggctagg 720ggagttactt atgaagagac tatagaagta aagcaagcac ctcttatgat agccgaaaaa 780cccataaggc tagaagaatt tttaaccttt ggaggtcagg atttaaatat tattactagt 840gctatgaagg aaaaaatata taacaatctt ttagctaact atgaaaaaat agctactaga 900cttagtgaag ttaatagtgc tcctcctgaa tatgatatta atgaatataa agattatttt 960caatggaagt atgggctaga taaaaatgct gatggaagtt atactgtaaa tgaaaataaa 1020tttaatgaaa tttataaaaa attatatagt tttacagaga gtgacttagc aaataaattt 1080aaagtaaaat gtagaaatac ttattttatt aaatatgaat ttttaaaagt tccaaatttg 1140ttagatgatg atatttatac tgtatcagag gggtttaata taggtaattt agcagtaaac 1200aatcgcggac aaagtataaa gttaaatcct aaaattattg attccattcc agataaaggt 1260ctagtagaaa agatcgttaa attttgtaag agcgttattc ctagaaaagg tacaaaggcg 1320ccaccgcgac tatgcattag agtaaataat agtgagttat tttttgtagc ttcagaaagt 1380agctataatg aaaatgatat taatacacct aaagaaattg acgatacaac aaatctaaat 1440aataattata gaaataattt agatgaagtt attttagatt ataatagtca gacaatacct 1500caaatatcaa atcgaacatt aaatacactt gtacaagaca atagttatgt gccaagatat 1560gattctaatg gaacaagtga aatagaggaa tatgatgttg ttgactttaa tgtatttttc 1620tatttacatg cacaaaaagt gccagaaggt gaaaccaata taagtttaac ttcttcaatt 1680gatacagcat tattagaaga atccaaagat atattttttt cttcagagtt tatcgatact 1740atcaataaac ctgtaaatgc agcactattt atagattgga taagcaaagt aataagagat 1800tttaccactg aagctacaca aaaaagtact gttgataaga ttgcagacat atctttaatt 1860gtaccctatg taggtcttgc tttgaatata attattgagg cagaaaaagg aaattttgag 1920gaggcatttg aattattagg agtgggtatt ttattagaat ttgtgccaga acttacaatt 1980cctgtaattt tagtgtttac gataaaatcc tatatagatt catatgagaa taaaaataaa 2040gcaattaaag caataaataa ttcattaatc gaaagagaag caaagtggaa agaaatatat 2100agttggatag tatcaaattg gcttactaga attaatactc aatttaataa aagaaaagag 2160caaatgtatc aggctttaca aaatcaagta gatgcaataa aaacagcaat agaatataaa 2220tataataatt atacttcaga tgagaaaaat agacttgaat ctgaatataa tatcaataat 2280atagaagaag aattgaataa aaaagtttct ttagcaatga aaaatataga aagatttatg 2340acagaaagtt ctatatctta tttaatgaaa ttaataaatg aagccaaagt tggtaaatta 2400aaaaaatatg ataaccatgt taagagcgat ttattaaact atattctcga ccatagatca 2460atcttaggag agcagacaaa tgaattaagt gatttggtga ctagtacttt gaatagtagt 2520attccatttg aactttcttc atatactaat gataaaattc taattatata ttttaataga 2580ttatataaaa aaattaaaga tagttctatt ttagatatgc gatatgaaaa taataaattt 2640atagatatct ctggatatgg ttcaaatata agcattaatg gaaacgtata tatttattca 2700acaaatagaa atcaatttgg aatatataat agtaggctta gtgaagttaa tatagctcaa 2760aataatgata ttatatagaa tagtagatat caaaatttta gtattagttt ctgggtaagg 2820attcctaaac actagaaacc tatgaatcat aatcgggaat agactataat aaattgtatg 2880gggaataata attcgggatg gaaaatatca cttagaactg ttagagattg tgaaataatt

2940tggactttac aagatacttc tggaaataag gaaaatttaa tttttaggta tgaagaactt 3000aataggatat ctaattatat aaataaatgg atttttgtaa ctattactaa taatagatta 3060ggcaattcta gaatttagat caatggaaat ttaatagttg aaaaatcaat ttcgaattta 3120ggtgatattc atgttagtga taatatatta tttaaaattg ttggttgtga tgatgaaacg 3180tatgttggta taagatattt taaagttttt aatacggaat tagataaaac agaaattgag 3240actttatata gtaatgagcc agatccaagt atcttaaaaa actattgggg aaattatttg 3300ctatataata aaaaatatta tttattcaat ttactaagaa aagataagta tattactctg 3360aattcaggca ttttaaatat taatcaacaa agaggtgtta ctgaaggctc tgtttttttg 3420aactataaat tatatgaagg agtagaagtc attataagaa aaaatggtcc tatagatata 3480tctaatacag ataattttgt tagaaaaaac gatctagcat acattaatgt agtagatcgt 3540ggtgtagaat atcggttata tgctgataca aaatcagaga aagagaaaat aataagaaca 3600tctaatctaa acgatagctt aggtcaaatt atagttatgg attcaatagg aaataattgc 3660acaatgaatt ttcaaaacaa taatgggagc aatataggat tactaggttt tcattcaaat 3720aatttggttg ctagtagttg gtattataac aatatacgaa gaaatactag cagtaatgga 3780tgcttttgga gttctatttc taaagagaat ggatggaaag aatga 382593894DNAArtificial SequenceDescription of Artificial Sequence synthetic primers used to introduce Stu I and EcoR I restriction sites into the 5' and 3' ends of the BoNT/A-L chain gene fragment 9atgccagtta atataaaaaa ctttaattat aatgacccta ttaataatga tgacattatt 60atgatggaac cattcaatga cccagggcca ggaacatatt ataaagcttt taggattata 120gatcgtattt ggatagtacc agaaaggttt acttatggat ttcaacctga ccaatttaat 180gccagtacag gagtttttag taaagatgtc tacgaatatt aggatccaac ttatttaaaa 240accgatgctg aaaaagataa atttttaaaa acaatgatta aattatttaa tagaattaat 300tcaaaaccat caggacagag attactggat atgatagtag atgctatacc ttatcttgga 360aatgcatcta caccgcccga caaatttgca gcaaatgttg caaatgtatc tattaataaa 420aaaattatcc aacctggagc tgaagatcaa ataaaaggtt taatgacaaa tttaataata 480tttggaccag gaccagttct aagtgataat tttactgata gtatgattat gaatggccat 540tccccaatat cagaaggatt tggtgcaaga atgatgataa gattttgtcc tagttgttta 600aatgtattta ataatgttca ggaaaataaa gatacatcta tatttagtag acgcgcgtat 660tttgcagatc cagctctaac gttaatgcat gaacttatac atgtgttaca tggattatat 720ggaattaaga taagtaattt accaattact ccaaatacaa aagaattttt catgcaacat 780agcgatcctg tacaagcaga agaactatat acattcggag gacatgatcc tagtgttata 840agtccttcta cggatatgaa tatttataat aaagcgttac aaaattttca agatatagct 900aataggctta atattgtttc aagtgcccaa gggagtggaa ttgatatttc cttatataaa 960caaatatata aaaataaata tgattttgtt gaagatccta atggaaaata tagtgtagat 1020aaggataagt ttgataaatt atataaggcc ttaatgtttg gctttactga aactaatcta 1080gctggtgaat atggaataaa aactaggtat tcttatttta gtgaatattt gccaccgata 1140aaaactgaaa aattgttaga caatacaatt tatactcaaa atgaaggctt taacatagct 1200agtaaaaatc tcaaaacgga atttaatggt cagaataagg cggtaaataa agaggcttat 1260gaagaaatca gcctagaaca tctcgttata tatagaatag caatgtgcaa gcctgtaatg 1320tacaaaaata ccggtaaatc tgaacagtgt attattgtta ataatgagga tttatttttc 1380atagctaata aagatagttt ttcaaaagat ttagctaaag cagaaactat agcatataat 1440acacaaaata atactataga aaataatttt tctatagatc agttgatttt agataatgat 1500ttaagcagtg gcatagactt accaaatgaa aacacagaac catttacaaa ttttgacgac 1560atagatatcc ctgtgtatat taaacaatct gctttaaaaa aaatttttgt ggatggagat 1620agcctttttg aatatttaca tgctcaaaca tttccttcta atatagaaaa tctacaacta 1680acgaattcat taaatgatgc tttaagaaat aataataaag tctatacttt tttttctaca 1740aaccttgttg aaaaagctaa tacagttgta ggtgcttcac tttttgtaaa ctgggtaaaa 1800ggagtaatag atgattttac atctgaatcc acacaaaaaa gtactataga taaagtttca 1860gatgtatcca taattattcc ctatatagga cctgctttga atgtaggaaa tgaaacagct 1920aaagaaaatt ttaaaaatgc ttttgaaata ggtggagccg ctatcttaat ggagtttatt 1980ccagaactta ttgtacctat agttggattt tttacattag aatcatatgt aggaaataaa 2040gggcatatta ttatgacgat atccaatgct ttaaagaaaa gggatcaaaa atggacagat 2100atgtatggtt tgatagtatc gcagtggctc tcaacggtta atactcaatt ttatacaata 2160aaagaaagaa tgtagaatgc tttaaataat caatcacaag caatagaaaa aataatagaa 2220gatcaatata atagatatag tgaagaagat aaaatgaata ttaacattga ttttaatgat 2280atagatttta aacttaatca aagtataaat ttagcaataa acaatataga tgattttata 2340aaccaatgtt ctatatcata tctaatgaat agaatgattc cattagctgt aaaaaagtta 2400aaagactttg atgataatct taagagagat ttattggagt atatagatac aaatgaacta 2460tatttacttg atgaagtaaa tattctaaaa tcaaaagtaa atagacacct aaaagacagt 2520ataccatttg atctttcact atataccaag gacacaattt taatacaagt ttttaataat 2580tatattagta atattagtag taatgctatt ttaagtttaa gttatagagg tgggcgttta 2640atagattcat ctggatatgg tgcaactatg aatgtaggtt cagatgttat ctttaatgat 2700ataggaaatg gtcaatttaa attaaataat tctgaaaata gtaatattac ggcacatcaa 2760agtaaattcg ttgtatatga tagtatgttt gataatttta gcattaactt ttgggtaagg 2820actcctaaat ataataataa tgatatacaa acttatcttc aaaatgagta tacaataatt 2880agttgtataa aaaatgactc aggatggaaa gtatctatta agggaaatag aataatatgg 2940acattaatag atgttaatgc aaaatctaaa tcaatatttt tcgaatatag tataaaagat 3000aatatatcag attatataaa taaatggttt tccataacta ttactaatga tagattaggt 3060aacgcaaata tttatataaa tggaagtttg aaaaaaagtg aaaaaatttt aaacttagat 3120agaattaatt ctagtaatga tatagacttc aaattaatta attgtacaga tactactaaa 3180tttgtttgga ttaaggattt taatattttt ggtagagaat taaatgctac agaagtatct 3240tcactatatt ggattcaatc atctacaaat actttaaaag atttttgggg gaatccttta 3300agataggata cacaatacta tctgtttaat caaggtatgc aaaatatcta tataaagtat 3360tttagtaaag cttctatggg ggaaactgca ccacgtacaa actttaataa tgcagcaata 3420aattatcaaa atttatatct tggtttacga tttattataa aaaaagcatc aaattctcgg 3480aatataaata atgataatat agtcagagaa ggagattata tatatcttaa tattgataat 3540atttctgatg aatcttagag agtatatgtt ttggtgaatt ctaaagaaat tcaaactcaa 3600ttatttttag cacccataaa tgatgatcct acgttctatg atgtactaca aataaaaaaa 3660tattatgaaa aaacaacata taattgtcag atactttgcg aaaaagatac taaaacattt 3720gggctgtttg gaattggtaa atttgttaaa gattatggat atgtttggga tacctatgat 3780aattattttt gcataagtca gtggtatctc agaagaatat ctgaaaatat aaataaatta 3840aggttgggat gtaattggca attcattccc gtggatgaag gatggacaga ataa 38941023DNAArtificial SequenceDescription of Artificial Sequence oligonucleotide used to introduce Stu I and EcoR I into BoNT/A-L chain gene fragments 10aaaggccttt tgttaataaa caa 231126DNAUnknown OrganismDescription of Artificial Sequence oligonucleotide used to introduce Stu I and EcoR I into BoNT/A-L chain gene fragment 11ggaattctta cttattgtat ccttta 261213PRTArtificial SequenceDescription of Artificial Sequence polypeptide fragment used to raise antibodies 12Cys Ala Asn Gln Arg Ala Thr Lys Met Leu Gly Ser Gly 1 5 10

Claims

1-35. (canceled)

36. A method for treating pain associated with postherpetic neuralgia in a patient in need thereof, the method comprising the step of locally administering a therapeutically effective amount of a botulinum toxin in powder form to a patient using a needleless injector, wherein the pain associated with the postherpetic neuralgia is thereby alleviated within 1 to 7 days of the local administration of the botulinum toxin to the patient.

37. The method of claim 36, wherein the needless injector has an elongated tubular nozzle and the needleless injector is connected to or connectable to means for producing a gas flow.

38. The method of claim 37, wherein means for producing gas flow is an energizing means.

39. The method of claim 37, wherein the gas flow is supersonic.

40. The method of claim 38, wherein the energizing means is a compressed gas tank containing an inert compressed gas.

41. The method of claim 40, wherein the inert compressed gas is helium.

42. The method of claim 36, wherein the botulinum toxin is administered with a carrier made of a solid material, the solid material selected from the group consisting of gold, platinum, tungsten and an ice crystal.

43. The method of claim 36, wherein the pain associated with postherpetic neuralgia is localized to an abdominal region of the patient.

44. The method of claim 36, wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, B, C.sub.1, D, E, F and G.

45. A method for treating pain associated with postherpetic neuralgia in a patient in need thereof, the method comprising the step of locally administering a therapeutically effective amount of botulinum toxin type A or B in powder form intradermally to a patient using a needleless injector connected to or connectable to means for producing a supersonic gas flow, wherein the pain associated with the postherpetic neuralgia is thereby alleviated within 1 to 7 days.

46. The method of claim 45, wherein a duration of pain alleviation is provided that lasts from about 7 to about 27 months.

47. The method of claim 45, wherein pain associated with postherpetic neuralgia is in the thorax of the patient.

48. The method of claim 45, wherein pain associated with postherpetic neuralgia is localized to the abdomen of the patient and the step of locally administering the botulinum toxin is to the abdomen of the patient.

49. The method of claim 45, wherein the therapeutically effective amount of the botulinum toxin type A administered to the patient is between about 0.05 U/kg to about 2 U/kg.

50. A method for treating pain associated with postherpetic neuralgia in a patient in need thereof, the method comprising the step of administering locally a therapeutically effective amount of botulinum toxin type A in powder form, using a needleless injector connected to or connectable to energizing means for producing a supersonic gas flow to a patient having healed lesions and pain localized to an abdominal region, wherein administration of the therapeutically effective amount of botulinum toxin type A in powder form is intradermal and into the abdominal region, wherein pain localized to the abdominal region is thereby alleviated within 1 to 7 days of the local administration of the botulinum toxin.

51. The method of claim 50, wherein the botulinum toxin is administered with a carrier made of a solid material, wherein the solid material is selected from the group consisting of gold, platinum, tungsten and an ice crystal.

52. The method of claim 51, wherein the carrier has a diameter less than about 10 millimeters.

53. The method of claim 50, wherein a duration of the pain alleviation is provided that last from about 7 to about 27 months.